BR112020009592A2 - derivados de ácido oxoacridinil acético e métodos de uso - Google Patents

Info

Publication number

BR112020009592A2

BR112020009592A2 BR112020009592-3A BR112020009592A BR112020009592A2 BR 112020009592 A2 BR112020009592 A2 BR 112020009592A2 BR 112020009592 A BR112020009592 A BR 112020009592A BR 112020009592 A2 BR112020009592 A2 BR 112020009592A2

Authority

BR

Brazil

Prior art keywords

alkyl

compound according

fact

halogen

cancer

Prior art date

2017-11-20

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 65
• 150000001242 acetic acid derivatives Chemical class 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 274
• 150000003839 salts Chemical class 0.000 claims abstract description 60
• 150000002148 esters Chemical class 0.000 claims abstract description 48
• 230000000694 effects Effects 0.000 claims abstract description 44
• 108010050904 Interferons Proteins 0.000 claims abstract description 8
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 385
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 192
• 229910052736 halogen Inorganic materials 0.000 claims description 130
• 150000002367 halogens Chemical group 0.000 claims description 126
• 201000010099 disease Diseases 0.000 claims description 89
• -1 C (O) O-C1- C6 alkyl Chemical group 0.000 claims description 80
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 73
• 125000005842 heteroatom Chemical group 0.000 claims description 50
• 229910052717 sulfur Inorganic materials 0.000 claims description 45
• 239000003814 drug Substances 0.000 claims description 42
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 41
• 229910052801 chlorine Inorganic materials 0.000 claims description 40
• 239000008194 pharmaceutical composition Substances 0.000 claims description 40
• 229910052760 oxygen Inorganic materials 0.000 claims description 39
• 125000000623 heterocyclic group Chemical group 0.000 claims description 35
• 230000003831 deregulation Effects 0.000 claims description 34
• 230000014509 gene expression Effects 0.000 claims description 31
• 125000001072 heteroaryl group Chemical group 0.000 claims description 31
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 30
• 238000011282 treatment Methods 0.000 claims description 29
• 229910052799 carbon Inorganic materials 0.000 claims description 25
• 229910052731 fluorine Inorganic materials 0.000 claims description 24
• 229910052794 bromium Inorganic materials 0.000 claims description 23
• 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 19
• 230000006662 intracellular pathway Effects 0.000 claims description 18
• 125000000217 alkyl group Chemical group 0.000 claims description 16
• 229910052727 yttrium Inorganic materials 0.000 claims description 14
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 13
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 13
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 12
• 125000003342 alkenyl group Chemical group 0.000 claims description 12
• 125000000304 alkynyl group Chemical group 0.000 claims description 12
• 239000003937 drug carrier Substances 0.000 claims description 12
• 230000002265 prevention Effects 0.000 claims description 12
• 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 11
• 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 11
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
• 238000004519 manufacturing process Methods 0.000 claims description 10
• 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 9
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
• 125000004432 carbon atom Chemical group C* 0.000 claims description 7
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
• 229910052757 nitrogen Inorganic materials 0.000 claims description 7
• 102000014150 Interferons Human genes 0.000 claims description 6
• 125000003118 aryl group Chemical group 0.000 claims description 6
• 239000011230 binding agent Substances 0.000 claims description 6
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 5
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
• 150000001721 carbon Chemical group 0.000 claims description 4
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 4
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 claims description 3
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 claims description 2
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 claims description 2
• 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims 15
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
• 125000005843 halogen group Chemical group 0.000 claims 4
• 229910052739 hydrogen Inorganic materials 0.000 claims 2
• 108090000623 proteins and genes Proteins 0.000 abstract description 52
• 102000004169 proteins and genes Human genes 0.000 abstract description 50
• 230000027455 binding Effects 0.000 abstract description 14
• 208000035475 disorder Diseases 0.000 description 102
• 239000000460 chlorine Substances 0.000 description 98
• 206010028980 Neoplasm Diseases 0.000 description 89
• 210000004027 cell Anatomy 0.000 description 82
• 230000002062 proliferating effect Effects 0.000 description 73
• 201000011510 cancer Diseases 0.000 description 58
• 239000002131 composite material Substances 0.000 description 54
• 235000018102 proteins Nutrition 0.000 description 49
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 45
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 43
• 235000002639 sodium chloride Nutrition 0.000 description 42
• 239000003795 chemical substances by application Substances 0.000 description 36
• 239000000203 mixture Substances 0.000 description 36
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 36
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 35
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 34
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 32
• 102100040678 Programmed cell death protein 1 Human genes 0.000 description 31
• 230000006870 function Effects 0.000 description 29
• 101710089372 Programmed cell death protein 1 Proteins 0.000 description 26
• 239000003112 inhibitor Substances 0.000 description 26
• 239000000556 agonist Substances 0.000 description 22
• 229940124597 therapeutic agent Drugs 0.000 description 21
• 108020004414 DNA Proteins 0.000 description 20
• 230000001413 cellular effect Effects 0.000 description 20
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 20
• 206010009944 Colon cancer Diseases 0.000 description 19
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 19
• 210000003491 skin Anatomy 0.000 description 18
• 230000001404 mediated effect Effects 0.000 description 17
• 239000002253 acid Substances 0.000 description 16
• 210000004072 lung Anatomy 0.000 description 16
• 208000011580 syndromic disease Diseases 0.000 description 16
• 102000053602 DNA Human genes 0.000 description 15
• 210000000481 breast Anatomy 0.000 description 15
• 208000029742 colonic neoplasm Diseases 0.000 description 15
• 229940079593 drug Drugs 0.000 description 15
• 230000003834 intracellular effect Effects 0.000 description 15
• 230000003902 lesion Effects 0.000 description 15
• 239000000126 substance Substances 0.000 description 15
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 14
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 14
• 206010025323 Lymphomas Diseases 0.000 description 14
• 201000005202 lung cancer Diseases 0.000 description 14
• 208000020816 lung neoplasm Diseases 0.000 description 14
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 13
• 210000001072 colon Anatomy 0.000 description 13
• 229960003301 nivolumab Drugs 0.000 description 13
• 239000000243 solution Substances 0.000 description 13
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 12
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 12
• 108010014726 Interferon Type I Proteins 0.000 description 12
• 102000002227 Interferon Type I Human genes 0.000 description 12
• SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 12
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 12
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 12
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 12
• 206010020718 hyperplasia Diseases 0.000 description 12
• 201000001441 melanoma Diseases 0.000 description 12
• 238000003786 synthesis reaction Methods 0.000 description 12
• 201000009030 Carcinoma Diseases 0.000 description 11
• 206010058314 Dysplasia Diseases 0.000 description 11
• 239000005557 antagonist Substances 0.000 description 11
• 239000002246 antineoplastic agent Substances 0.000 description 11
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 11
• 210000001672 ovary Anatomy 0.000 description 11
• 201000002528 pancreatic cancer Diseases 0.000 description 11
• 208000008443 pancreatic carcinoma Diseases 0.000 description 11
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 10
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 10
• 210000001744 T-lymphocyte Anatomy 0.000 description 10
• 230000004913 activation Effects 0.000 description 10
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 10
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 10
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 10
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 10
• 229960002621 pembrolizumab Drugs 0.000 description 10
• 210000002307 prostate Anatomy 0.000 description 10
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 9
• 208000003174 Brain Neoplasms Diseases 0.000 description 9
• 206010006187 Breast cancer Diseases 0.000 description 9
• 208000026310 Breast neoplasm Diseases 0.000 description 9
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 9
• 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 9
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
• 206010054949 Metaplasia Diseases 0.000 description 9
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 9
• 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 description 9
• 230000012010 growth Effects 0.000 description 9
• 230000002401 inhibitory effect Effects 0.000 description 9
• 239000003446 ligand Substances 0.000 description 9
• 230000015689 metaplastic ossification Effects 0.000 description 9
• 210000000496 pancreas Anatomy 0.000 description 9
• 210000001519 tissue Anatomy 0.000 description 9
• 239000003970 toll like receptor agonist Substances 0.000 description 9
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 8
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 8
• 108010092160 Dactinomycin Proteins 0.000 description 8
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 8
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 8
• 208000012902 Nervous system disease Diseases 0.000 description 8
• 208000006994 Precancerous Conditions Diseases 0.000 description 8
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 8
• 102000002689 Toll-like receptor Human genes 0.000 description 8
• 108020000411 Toll-like receptor Proteins 0.000 description 8
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 8
• 239000002671 adjuvant Substances 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 208000032839 leukemia Diseases 0.000 description 8
• 239000000463 material Substances 0.000 description 8
• 206010061289 metastatic neoplasm Diseases 0.000 description 8
• 210000000056 organ Anatomy 0.000 description 8
• 238000002360 preparation method Methods 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 8
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 8
• 108010024976 Asparaginase Proteins 0.000 description 7
• 241000283690 Bos taurus Species 0.000 description 7
• 229940045513 CTLA4 antagonist Drugs 0.000 description 7
• 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 7
• 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 7
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 7
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
• XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 7
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 7
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 7
• 206010039491 Sarcoma Diseases 0.000 description 7
• 208000000453 Skin Neoplasms Diseases 0.000 description 7
• 208000009956 adenocarcinoma Diseases 0.000 description 7
• 229960000473 altretamine Drugs 0.000 description 7
• 239000002585 base Substances 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 230000022131 cell cycle Effects 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 230000001684 chronic effect Effects 0.000 description 7
• 229960002436 cladribine Drugs 0.000 description 7
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 7
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 7
• 206010017758 gastric cancer Diseases 0.000 description 7
• 210000000987 immune system Anatomy 0.000 description 7
• 239000002955 immunomodulating agent Substances 0.000 description 7
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 7
• 230000001394 metastastic effect Effects 0.000 description 7
• 229960000485 methotrexate Drugs 0.000 description 7
• 229960001592 paclitaxel Drugs 0.000 description 7
• 229960001972 panitumumab Drugs 0.000 description 7
• 244000052769 pathogen Species 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 102000020233 phosphotransferase Human genes 0.000 description 7
• 239000000843 powder Substances 0.000 description 7
• 201000000849 skin cancer Diseases 0.000 description 7
• 230000004936 stimulating effect Effects 0.000 description 7
• 239000003981 vehicle Substances 0.000 description 7
• 208000030507 AIDS Diseases 0.000 description 6
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 6
• 208000023275 Autoimmune disease Diseases 0.000 description 6
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 6
• 108010006654 Bleomycin Proteins 0.000 description 6
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 6
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 6
• 239000005977 Ethylene Substances 0.000 description 6
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 6
• 208000025966 Neurological disease Diseases 0.000 description 6
• 229930012538 Paclitaxel Natural products 0.000 description 6
• 108091000080 Phosphotransferase Proteins 0.000 description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 208000005718 Stomach Neoplasms Diseases 0.000 description 6
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 6
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
• 239000000427 antigen Substances 0.000 description 6
• 108091007433 antigens Proteins 0.000 description 6
• 102000036639 antigens Human genes 0.000 description 6
• 229940034982 antineoplastic agent Drugs 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 230000001580 bacterial effect Effects 0.000 description 6
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 6
• 229960000684 cytarabine Drugs 0.000 description 6
• 229960000975 daunorubicin Drugs 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• 239000000499 gel Substances 0.000 description 6
• 229940088597 hormone Drugs 0.000 description 6
• 239000005556 hormone Substances 0.000 description 6
• 239000000543 intermediate Substances 0.000 description 6
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 6
• 239000002674 ointment Substances 0.000 description 6
• 201000008968 osteosarcoma Diseases 0.000 description 6
• 230000001717 pathogenic effect Effects 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 239000000047 product Substances 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• 201000011549 stomach cancer Diseases 0.000 description 6
• 239000003826 tablet Substances 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 238000002560 therapeutic procedure Methods 0.000 description 6
• WDPVNDRNBJNETA-JBLDHEPKSA-N (2s)-2-amino-6-[[(2s)-1-[[(1r)-1-carboxy-2-methylpropyl]amino]-1-oxo-4-sulfanylbutan-2-yl]amino]-6-oxohexanoic acid Chemical compound CC(C)[C@H](C(O)=O)NC(=O)[C@H](CCS)NC(=O)CCC[C@H](N)C(O)=O WDPVNDRNBJNETA-JBLDHEPKSA-N 0.000 description 5
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 5
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 5
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
• 208000024827 Alzheimer disease Diseases 0.000 description 5
• 102000015790 Asparaginase Human genes 0.000 description 5
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 5
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 5
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 5
• 206010009900 Colitis ulcerative Diseases 0.000 description 5
• 208000011231 Crohn disease Diseases 0.000 description 5
• 102000004127 Cytokines Human genes 0.000 description 5
• 108090000695 Cytokines Proteins 0.000 description 5
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 5
• 206010012289 Dementia Diseases 0.000 description 5
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 5
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 5
• 208000002193 Pain Diseases 0.000 description 5
• 206010060862 Prostate cancer Diseases 0.000 description 5
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
• 206010037660 Pyrexia Diseases 0.000 description 5
• 229920002472 Starch Polymers 0.000 description 5
• 208000006011 Stroke Diseases 0.000 description 5
• NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 5
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 5
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 5
• 201000006704 Ulcerative Colitis Diseases 0.000 description 5
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
• 229940100198 alkylating agent Drugs 0.000 description 5
• 239000002168 alkylating agent Substances 0.000 description 5
• 230000001028 anti-proliverative effect Effects 0.000 description 5
• 229960000397 bevacizumab Drugs 0.000 description 5
• 239000012472 biological sample Substances 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 5
• 239000006071 cream Substances 0.000 description 5
• 229960004397 cyclophosphamide Drugs 0.000 description 5
• 229940127089 cytotoxic agent Drugs 0.000 description 5
• 229960000640 dactinomycin Drugs 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 230000008482 dysregulation Effects 0.000 description 5
• 239000002158 endotoxin Substances 0.000 description 5
• 229960000961 floxuridine Drugs 0.000 description 5
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 5
• 210000005096 hematological system Anatomy 0.000 description 5
• 229940022353 herceptin Drugs 0.000 description 5
• 229960001330 hydroxycarbamide Drugs 0.000 description 5
• 230000002519 immonomodulatory effect Effects 0.000 description 5
• 229940121354 immunomodulator Drugs 0.000 description 5
• 229940043355 kinase inhibitor Drugs 0.000 description 5
• 239000008101 lactose Substances 0.000 description 5
• 208000014018 liver neoplasm Diseases 0.000 description 5
• 201000004792 malaria Diseases 0.000 description 5
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
• 229960004857 mitomycin Drugs 0.000 description 5
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 5
• 208000015122 neurodegenerative disease Diseases 0.000 description 5
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
• 239000003921 oil Substances 0.000 description 5
• 235000019198 oils Nutrition 0.000 description 5
• FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 5
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 5
• 239000012071 phase Substances 0.000 description 5
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
• 239000003755 preservative agent Substances 0.000 description 5
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 5
• HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 5
• 241000894007 species Species 0.000 description 5
• 235000019698 starch Nutrition 0.000 description 5
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 5
• 239000000829 suppository Substances 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• UXXQOJXBIDBUAC-UHFFFAOYSA-N tandutinib Chemical compound COC1=CC2=C(N3CCN(CC3)C(=O)NC=3C=CC(OC(C)C)=CC=3)N=CN=C2C=C1OCCCN1CCCCC1 UXXQOJXBIDBUAC-UHFFFAOYSA-N 0.000 description 5
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 5
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
• JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 5
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 5
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
• 208000031277 Amaurotic familial idiocy Diseases 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 208000035143 Bacterial infection Diseases 0.000 description 4
• 208000018084 Bone neoplasm Diseases 0.000 description 4
• 108091007914 CDKs Proteins 0.000 description 4
• 206010006895 Cachexia Diseases 0.000 description 4
• 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
• 208000007465 Giant cell arteritis Diseases 0.000 description 4
• 206010018338 Glioma Diseases 0.000 description 4
• 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 4
• 101000643024 Homo sapiens Stimulator of interferon genes protein Proteins 0.000 description 4
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 4
• 241000725303 Human immunodeficiency virus Species 0.000 description 4
• 208000023105 Huntington disease Diseases 0.000 description 4
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 4
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
• 102000042838 JAK family Human genes 0.000 description 4
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 4
• 208000000172 Medulloblastoma Diseases 0.000 description 4
• 208000034578 Multiple myelomas Diseases 0.000 description 4
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 4
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 4
• 206010033128 Ovarian cancer Diseases 0.000 description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 description 4
• 208000018737 Parkinson disease Diseases 0.000 description 4
• 206010035664 Pneumonia Diseases 0.000 description 4
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 4
• 206010038389 Renal cancer Diseases 0.000 description 4
• 201000000582 Retinoblastoma Diseases 0.000 description 4
• 206010040047 Sepsis Diseases 0.000 description 4
• 206010040070 Septic Shock Diseases 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 4
• 208000024770 Thyroid neoplasm Diseases 0.000 description 4
• 102100039360 Toll-like receptor 4 Human genes 0.000 description 4
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
• 201000004810 Vascular dementia Diseases 0.000 description 4
• 208000036142 Viral infection Diseases 0.000 description 4
• 238000010521 absorption reaction Methods 0.000 description 4
• 239000004480 active ingredient Substances 0.000 description 4
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 4
• 150000001413 amino acids Chemical group 0.000 description 4
• GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 4
• 229940120638 avastin Drugs 0.000 description 4
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 4
• 208000022362 bacterial infectious disease Diseases 0.000 description 4
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 4
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 4
• 208000002458 carcinoid tumor Diseases 0.000 description 4
• 229960005243 carmustine Drugs 0.000 description 4
• 229960005395 cetuximab Drugs 0.000 description 4
• 238000000576 coating method Methods 0.000 description 4
• 230000006378 damage Effects 0.000 description 4
• 229960002448 dasatinib Drugs 0.000 description 4
• 229960003603 decitabine Drugs 0.000 description 4
• DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical class C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 4
• 229950009791 durvalumab Drugs 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 229940082789 erbitux Drugs 0.000 description 4
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 4
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 4
• 229960005420 etoposide Drugs 0.000 description 4
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 4
• 208000005017 glioblastoma Diseases 0.000 description 4
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
• 102000048362 human PDCD1 Human genes 0.000 description 4
• 102000050022 human STING1 Human genes 0.000 description 4
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 4
• 210000002865 immune cell Anatomy 0.000 description 4
• 239000003022 immunostimulating agent Substances 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 239000003701 inert diluent Substances 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 229960005280 isotretinoin Drugs 0.000 description 4
• 229960004891 lapatinib Drugs 0.000 description 4
• RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 4
• 229920006008 lipopolysaccharide Polymers 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 201000007270 liver cancer Diseases 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 208000005264 motor neuron disease Diseases 0.000 description 4
• 210000000214 mouth Anatomy 0.000 description 4
• 201000006417 multiple sclerosis Diseases 0.000 description 4
• 201000000050 myeloid neoplasm Diseases 0.000 description 4
• LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 4
• 230000009826 neoplastic cell growth Effects 0.000 description 4
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 4
• 230000002611 ovarian Effects 0.000 description 4
• 239000006072 paste Substances 0.000 description 4
• 102000007863 pattern recognition receptors Human genes 0.000 description 4
• 108010089193 pattern recognition receptors Proteins 0.000 description 4
• 208000033808 peripheral neuropathy Diseases 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 229940002612 prodrug Drugs 0.000 description 4
• 239000000651 prodrug Substances 0.000 description 4
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 4
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 4
• 210000005267 prostate cell Anatomy 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
• 229960004641 rituximab Drugs 0.000 description 4
• 229950004707 rucaparib Drugs 0.000 description 4
• 238000007127 saponification reaction Methods 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 206010041823 squamous cell carcinoma Diseases 0.000 description 4
• 239000007858 starting material Substances 0.000 description 4
• 238000013456 study Methods 0.000 description 4
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 4
• 229960001796 sunitinib Drugs 0.000 description 4
• 229940034785 sutent Drugs 0.000 description 4
• 238000010189 synthetic method Methods 0.000 description 4
• 201000002510 thyroid cancer Diseases 0.000 description 4
• 229960000575 trastuzumab Drugs 0.000 description 4
• 229960001727 tretinoin Drugs 0.000 description 4
• 210000004881 tumor cell Anatomy 0.000 description 4
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 4
• 229960004528 vincristine Drugs 0.000 description 4
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 239000001993 wax Substances 0.000 description 4
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 3
• 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 3
• XRILCFTWUCUKJR-INFSMZHSSA-N 2'-3'-cGAMP Chemical compound C([C@H]([C@H]1O)O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H]2N1C=NC2=C1NC(N)=NC2=O XRILCFTWUCUKJR-INFSMZHSSA-N 0.000 description 3
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 3
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
• 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 3
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 3
• 201000011452 Adrenoleukodystrophy Diseases 0.000 description 3
• 206010061424 Anal cancer Diseases 0.000 description 3
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 3
• 241000416162 Astragalus gummifer Species 0.000 description 3
• 206010004593 Bile duct cancer Diseases 0.000 description 3
• 206010005003 Bladder cancer Diseases 0.000 description 3
• 206010005949 Bone cancer Diseases 0.000 description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 3
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 3
• 206010011831 Cytomegalovirus infection Diseases 0.000 description 3
• 230000006820 DNA synthesis Effects 0.000 description 3
• 201000004624 Dermatitis Diseases 0.000 description 3
• 206010014733 Endometrial cancer Diseases 0.000 description 3
• 206010014759 Endometrial neoplasm Diseases 0.000 description 3
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• 108010040721 Flagellin Proteins 0.000 description 3
• 201000011240 Frontotemporal dementia Diseases 0.000 description 3
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
• 208000021309 Germ cell tumor Diseases 0.000 description 3
• 208000008999 Giant Cell Carcinoma Diseases 0.000 description 3
• 208000032612 Glial tumor Diseases 0.000 description 3
• 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
• 108010069236 Goserelin Proteins 0.000 description 3
• 208000017604 Hodgkin disease Diseases 0.000 description 3
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
• 241000282412 Homo Species 0.000 description 3
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 3
• 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 3
• 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 3
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 3
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 108010078049 Interferon alpha-2 Proteins 0.000 description 3
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• 102000000588 Interleukin-2 Human genes 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 206010023076 Isosporiasis Diseases 0.000 description 3
• 208000028226 Krabbe disease Diseases 0.000 description 3
• HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
• 108090001030 Lipoproteins Proteins 0.000 description 3
• 102000004895 Lipoproteins Human genes 0.000 description 3
• 208000019693 Lung disease Diseases 0.000 description 3
• 208000002569 Machado-Joseph Disease Diseases 0.000 description 3
• 208000005767 Megalencephaly Diseases 0.000 description 3
• 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 3
• 206010027406 Mesothelioma Diseases 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
• 208000003445 Mouth Neoplasms Diseases 0.000 description 3
• 208000001089 Multiple system atrophy Diseases 0.000 description 3
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 3
• 206010029260 Neuroblastoma Diseases 0.000 description 3
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
• 208000001132 Osteoporosis Diseases 0.000 description 3
• 239000012661 PARP inhibitor Substances 0.000 description 3
• 239000012271 PD-L1 inhibitor Substances 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 3
• 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
• 208000024777 Prion disease Diseases 0.000 description 3
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 3
• 102000001253 Protein Kinase Human genes 0.000 description 3
• 208000005587 Refsum Disease Diseases 0.000 description 3
• 208000006265 Renal cell carcinoma Diseases 0.000 description 3
• 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 3
• 102000014400 SH2 domains Human genes 0.000 description 3
• 108050003452 SH2 domains Proteins 0.000 description 3
• 102000000395 SH3 domains Human genes 0.000 description 3
• 108050008861 SH3 domains Proteins 0.000 description 3
• 206010061934 Salivary gland cancer Diseases 0.000 description 3
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• 208000021386 Sjogren Syndrome Diseases 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 3
• 208000031726 Spotted Fever Group Rickettsiosis Diseases 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• 241000282887 Suidae Species 0.000 description 3
• 229940123237 Taxane Drugs 0.000 description 3
• 102100024333 Toll-like receptor 2 Human genes 0.000 description 3
• 102100024324 Toll-like receptor 3 Human genes 0.000 description 3
• 229920001615 Tragacanth Polymers 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 241000223109 Trypanosoma cruzi Species 0.000 description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
• 108091008605 VEGF receptors Proteins 0.000 description 3
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• FZEYVTFCMJSGMP-UHFFFAOYSA-N acridone Chemical class C1=CC=C2C(=O)C3=CC=CC=C3NC2=C1 FZEYVTFCMJSGMP-UHFFFAOYSA-N 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 230000001154 acute effect Effects 0.000 description 3
• 201000008395 adenosquamous carcinoma Diseases 0.000 description 3
• 230000029936 alkylation Effects 0.000 description 3
• 238000005804 alkylation reaction Methods 0.000 description 3
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 229960002938 bexarotene Drugs 0.000 description 3
• 230000003115 biocidal effect Effects 0.000 description 3
• 229960001561 bleomycin Drugs 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 229960004562 carboplatin Drugs 0.000 description 3
• 239000001768 carboxy methyl cellulose Substances 0.000 description 3
• 230000000747 cardiac effect Effects 0.000 description 3
• 238000000423 cell based assay Methods 0.000 description 3
• 238000004113 cell culture Methods 0.000 description 3
• 230000030833 cell death Effects 0.000 description 3
• 229920002678 cellulose Polymers 0.000 description 3
• 239000001913 cellulose Substances 0.000 description 3
• 235000010980 cellulose Nutrition 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
• 229960004316 cisplatin Drugs 0.000 description 3
• 238000002648 combination therapy Methods 0.000 description 3
• 229940088547 cosmegen Drugs 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 229960003901 dacarbazine Drugs 0.000 description 3
• 229940107841 daunoxome Drugs 0.000 description 3
• 235000014113 dietary fatty acids Nutrition 0.000 description 3
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
• 229960003668 docetaxel Drugs 0.000 description 3
• 239000003995 emulsifying agent Substances 0.000 description 3
• 229960001904 epirubicin Drugs 0.000 description 3
• 239000000284 extract Substances 0.000 description 3
• 229930195729 fatty acid Natural products 0.000 description 3
• 239000000194 fatty acid Substances 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 229960002949 fluorouracil Drugs 0.000 description 3
• YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 3
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 3
• 239000012458 free base Substances 0.000 description 3
• 229940050411 fumarate Drugs 0.000 description 3
• 230000002496 gastric effect Effects 0.000 description 3
• 230000002489 hematologic effect Effects 0.000 description 3
• 238000005984 hydrogenation reaction Methods 0.000 description 3
• 230000003463 hyperproliferative effect Effects 0.000 description 3
• 229960000908 idarubicin Drugs 0.000 description 3
• 125000002883 imidazolyl group Chemical group 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 208000026278 immune system disease Diseases 0.000 description 3
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
• 238000000338 in vitro Methods 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 229940079322 interferon Drugs 0.000 description 3
• 229960005386 ipilimumab Drugs 0.000 description 3
• 208000003849 large cell carcinoma Diseases 0.000 description 3
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 239000006210 lotion Substances 0.000 description 3
• 239000000314 lubricant Substances 0.000 description 3
• 201000000014 lung giant cell carcinoma Diseases 0.000 description 3
• 230000003211 malignant effect Effects 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 229960004961 mechlorethamine Drugs 0.000 description 3
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 3
• 229960001924 melphalan Drugs 0.000 description 3
• DASQOOZCTWOQPA-GXKRWWSZSA-L methotrexate disodium Chemical compound [Na+].[Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 DASQOOZCTWOQPA-GXKRWWSZSA-L 0.000 description 3
• BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 3
• 229950010895 midostaurin Drugs 0.000 description 3
• 229960001156 mitoxantrone Drugs 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
• 229940086322 navelbine Drugs 0.000 description 3
• 208000004296 neuralgia Diseases 0.000 description 3
• 230000004770 neurodegeneration Effects 0.000 description 3
• 230000000926 neurological effect Effects 0.000 description 3
• 208000021722 neuropathic pain Diseases 0.000 description 3
• 229960002653 nilutamide Drugs 0.000 description 3
• PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 3
• 229950011068 niraparib Drugs 0.000 description 3
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 150000007523 nucleic acids Chemical class 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 229940121656 pd-l1 inhibitor Drugs 0.000 description 3
• 229960002340 pentostatin Drugs 0.000 description 3
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
• 235000021317 phosphate Nutrition 0.000 description 3
• 229940063179 platinol Drugs 0.000 description 3
• 229960000624 procarbazine Drugs 0.000 description 3
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 108060006633 protein kinase Proteins 0.000 description 3
• 230000002685 pulmonary effect Effects 0.000 description 3
• 229940117820 purinethol Drugs 0.000 description 3
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 206010038038 rectal cancer Diseases 0.000 description 3
• 208000037803 restenosis Diseases 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 208000000649 small cell carcinoma Diseases 0.000 description 3
• 210000000813 small intestine Anatomy 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 210000002784 stomach Anatomy 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 239000003765 sweetening agent Substances 0.000 description 3
• 230000002194 synthesizing effect Effects 0.000 description 3
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
• 239000000454 talc Substances 0.000 description 3
• 235000012222 talc Nutrition 0.000 description 3
• 229910052623 talc Inorganic materials 0.000 description 3
• 229960004964 temozolomide Drugs 0.000 description 3
• 206010043207 temporal arteritis Diseases 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 208000008732 thymoma Diseases 0.000 description 3
• 229960003087 tioguanine Drugs 0.000 description 3
• 230000000699 topical effect Effects 0.000 description 3
• 229960005267 tositumomab Drugs 0.000 description 3
• 235000010487 tragacanth Nutrition 0.000 description 3
• 239000000196 tragacanth Substances 0.000 description 3
• 229940116362 tragacanth Drugs 0.000 description 3
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 238000000844 transformation Methods 0.000 description 3
• VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 3
• 229940094060 tykerb Drugs 0.000 description 3
• 230000010472 type I IFN response Effects 0.000 description 3
• 201000005112 urinary bladder cancer Diseases 0.000 description 3
• 239000012646 vaccine adjuvant Substances 0.000 description 3
• 229940124931 vaccine adjuvant Drugs 0.000 description 3
• 229960003048 vinblastine Drugs 0.000 description 3
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 3
• MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 2
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
• HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 2
• FBFJOZZTIXSPPR-UHFFFAOYSA-N 1-(4-aminobutyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CCCCN)C3=C(N)N=C21 FBFJOZZTIXSPPR-UHFFFAOYSA-N 0.000 description 2
• 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 2
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 2
• CBIAKDAYHRWZCU-UHFFFAOYSA-N 2-bromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C(Br)=C1 CBIAKDAYHRWZCU-UHFFFAOYSA-N 0.000 description 2
• WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 2
• HOZUXBLMYUPGPZ-UHFFFAOYSA-N 4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1NC1=CC=C(O)C=C1 HOZUXBLMYUPGPZ-UHFFFAOYSA-N 0.000 description 2
• ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 2
• WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 2
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
• 206010001513 AIDS related complex Diseases 0.000 description 2
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
• BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 2
• 206010052075 Acquired epileptic aphasia Diseases 0.000 description 2
• 208000003200 Adenoma Diseases 0.000 description 2
• 206010001233 Adenoma benign Diseases 0.000 description 2
• 206010068873 Adenosquamous cell carcinoma Diseases 0.000 description 2
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
• ULXXDDBFHOBEHA-ONEGZZNKSA-N Afatinib Chemical compound N1=CN=C2C=C(OC3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-ONEGZZNKSA-N 0.000 description 2
• 229920001817 Agar Polymers 0.000 description 2
• 208000011403 Alexander disease Diseases 0.000 description 2
• 102100034452 Alternative prion protein Human genes 0.000 description 2
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
• 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 2
• 208000007860 Anus Neoplasms Diseases 0.000 description 2
• 206010002941 Apallic syndrome Diseases 0.000 description 2
• 206010003101 Arnold-Chiari Malformation Diseases 0.000 description 2
• 206010060971 Astrocytoma malignant Diseases 0.000 description 2
• 206010003591 Ataxia Diseases 0.000 description 2
• 102000007371 Ataxin-3 Human genes 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
• 241000271566 Aves Species 0.000 description 2
• 208000003950 B-cell lymphoma Diseases 0.000 description 2
• 206010004146 Basal cell carcinoma Diseases 0.000 description 2
• 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 2
• 101150013553 CD40 gene Proteins 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 208000009458 Carcinoma in Situ Diseases 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 208000015321 Chiari malformation Diseases 0.000 description 2
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
• 208000000094 Chronic Pain Diseases 0.000 description 2
• 241000202285 Claravis Species 0.000 description 2
• 208000003495 Coccidiosis Diseases 0.000 description 2
• 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
• 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 2
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
• 208000008953 Cryptosporidiosis Diseases 0.000 description 2
• 206010011502 Cryptosporidiosis infection Diseases 0.000 description 2
• 208000014311 Cushing syndrome Diseases 0.000 description 2
• 102000016736 Cyclin Human genes 0.000 description 2
• 108050006400 Cyclin Proteins 0.000 description 2
• 102100021906 Cyclin-O Human genes 0.000 description 2
• 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 2
• 241000224432 Entamoeba histolytica Species 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
• 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 208000000321 Gardner Syndrome Diseases 0.000 description 2
• 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 229940125497 HER2 kinase inhibitor Drugs 0.000 description 2
• 206010019280 Heart failures Diseases 0.000 description 2
• 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 2
• 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 2
• 208000007514 Herpes zoster Diseases 0.000 description 2
• 206010063491 Herpes zoster oticus Diseases 0.000 description 2
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
• 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 2
• 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 2
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
• 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 206010021143 Hypoxia Diseases 0.000 description 2
• 206010021750 Infantile Spasms Diseases 0.000 description 2
• 208000029523 Interstitial Lung disease Diseases 0.000 description 2
• 206010061252 Intraocular melanoma Diseases 0.000 description 2
• 208000032382 Ischaemic stroke Diseases 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• 208000027747 Kennedy disease Diseases 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
• 239000005536 L01XE08 - Nilotinib Substances 0.000 description 2
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
• UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 2
• 201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 2
• 208000004554 Leishmaniasis Diseases 0.000 description 2
• 108010000817 Leuprolide Proteins 0.000 description 2
• 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 2
• 208000004852 Lung Injury Diseases 0.000 description 2
• 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
• 201000005027 Lynch syndrome Diseases 0.000 description 2
• 201000009906 Meningitis Diseases 0.000 description 2
• XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 2
• 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 102000029749 Microtubule Human genes 0.000 description 2
• 108091022875 Microtubule Proteins 0.000 description 2
• 229930192392 Mitomycin Natural products 0.000 description 2
• 201000002983 Mobius syndrome Diseases 0.000 description 2
• 208000026072 Motor neurone disease Diseases 0.000 description 2
• 241000699666 Mus <mouse, genus> Species 0.000 description 2
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
• 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
• 206010028561 Myeloid metaplasia Diseases 0.000 description 2
• 206010028570 Myelopathy Diseases 0.000 description 2
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 2
• 208000010316 Myotonia congenita Diseases 0.000 description 2
• 150000001204 N-oxides Chemical class 0.000 description 2
• 208000008457 Neurologic Manifestations Diseases 0.000 description 2
• 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 2
• 208000014060 Niemann-Pick disease Diseases 0.000 description 2
• KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 2
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• 206010053854 Opsoclonus myoclonus Diseases 0.000 description 2
• 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 2
• 206010031127 Orthostatic hypotension Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 206010033799 Paralysis Diseases 0.000 description 2
• 208000000821 Parathyroid Neoplasms Diseases 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 2
• 206010034764 Peutz-Jeghers syndrome Diseases 0.000 description 2
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 2
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
• 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 2
• 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 2
• 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
• 208000032319 Primary lateral sclerosis Diseases 0.000 description 2
• 108091000054 Prion Proteins 0.000 description 2
• 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 2
• 108090000315 Protein Kinase C Proteins 0.000 description 2
• 102000003923 Protein Kinase C Human genes 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• 208000007531 Proteus syndrome Diseases 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 108091005682 Receptor kinases Proteins 0.000 description 2
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
• 208000015634 Rectal Neoplasms Diseases 0.000 description 2
• 206010063837 Reperfusion injury Diseases 0.000 description 2
• 230000018199 S phase Effects 0.000 description 2
• 229940044665 STING agonist Drugs 0.000 description 2
• XLBQNZICMYZIQT-GHXNOFRVSA-N SU5614 Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC(Cl)=CC=C2NC\1=O XLBQNZICMYZIQT-GHXNOFRVSA-N 0.000 description 2
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
• 208000021235 Schilder disease Diseases 0.000 description 2
• 201000010208 Seminoma Diseases 0.000 description 2
• 201000010001 Silicosis Diseases 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• 201000003696 Sotos syndrome Diseases 0.000 description 2
• 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 2
• 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
• 241000191967 Staphylococcus aureus Species 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• 229940124613 TLR 7/8 agonist Drugs 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• 244000299461 Theobroma cacao Species 0.000 description 2
• 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 2
• 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• 101710183280 Topoisomerase Proteins 0.000 description 2
• 241000223105 Trypanosoma brucei Species 0.000 description 2
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 2
• 206010046298 Upper motor neurone lesion Diseases 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 201000005969 Uveal melanoma Diseases 0.000 description 2
• 229940124304 VEGF/VEGFR inhibitor Drugs 0.000 description 2
• 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
• 229940122803 Vinca alkaloid Drugs 0.000 description 2
• 201000006791 West syndrome Diseases 0.000 description 2
• 208000008383 Wilms tumor Diseases 0.000 description 2
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
• XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
• CBPNZQVSJQDFBE-SREVRWKESA-N [(1S,2R,4S)-4-[(2R)-2-[(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32R,35R)-1,18-dihydroxy-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-2,3,10,14,20-pentaoxo-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraen-12-yl]propyl]-2-methoxycyclohexyl] 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate Chemical compound C[C@@H]1CC[C@@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC CBPNZQVSJQDFBE-SREVRWKESA-N 0.000 description 2
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
• 108010023617 abarelix Proteins 0.000 description 2
• AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 2
• 229960002184 abarelix Drugs 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 2
• 239000000853 adhesive Substances 0.000 description 2
• 230000001070 adhesive effect Effects 0.000 description 2
• 208000030597 adult Refsum disease Diseases 0.000 description 2
• 201000006966 adult T-cell leukemia Diseases 0.000 description 2
• 239000008272 agar Substances 0.000 description 2
• 235000010419 agar Nutrition 0.000 description 2
• 206010064930 age-related macular degeneration Diseases 0.000 description 2
• 108700025316 aldesleukin Proteins 0.000 description 2
• 229960000548 alemtuzumab Drugs 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 229940098174 alkeran Drugs 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 2
• 229940022824 amnesteem Drugs 0.000 description 2
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
• 229960001220 amsacrine Drugs 0.000 description 2
• 229960002932 anastrozole Drugs 0.000 description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 description 2
• 229940045799 anthracyclines and related substance Drugs 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 229940046836 anti-estrogen Drugs 0.000 description 2
• 230000001833 anti-estrogenic effect Effects 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 229940044684 anti-microtubule agent Drugs 0.000 description 2
• 230000000118 anti-neoplastic effect Effects 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• 239000002814 antineoplastic antimetabolite Substances 0.000 description 2
• 239000003443 antiviral agent Substances 0.000 description 2
• 201000011165 anus cancer Diseases 0.000 description 2
• 239000003886 aromatase inhibitor Substances 0.000 description 2
• 230000002917 arthritic effect Effects 0.000 description 2
• 239000010425 asbestos Substances 0.000 description 2
• 229960003272 asparaginase Drugs 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 229960003852 atezolizumab Drugs 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 208000019493 atypical carcinoid tumor Diseases 0.000 description 2
• 230000005784 autoimmunity Effects 0.000 description 2
• 229950002916 avelumab Drugs 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• 229960000997 bicalutamide Drugs 0.000 description 2
• 238000010256 biochemical assay Methods 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 206010005159 blepharospasm Diseases 0.000 description 2
• 230000000744 blepharospasm Effects 0.000 description 2
• 208000019664 bone resorption disease Diseases 0.000 description 2
• 229960003736 bosutinib Drugs 0.000 description 2
• UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 2
• 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 2
• 229950005993 brivanib alaninate Drugs 0.000 description 2
• LTEJRLHKIYCEOX-OCCSQVGLSA-N brivanib alaninate Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@@H](C)OC(=O)[C@H](C)N)=C1 LTEJRLHKIYCEOX-OCCSQVGLSA-N 0.000 description 2
• 239000006172 buffering agent Substances 0.000 description 2
• 229960002092 busulfan Drugs 0.000 description 2
• 235000019437 butane-1,3-diol Nutrition 0.000 description 2
• 235000014121 butter Nutrition 0.000 description 2
• 235000001046 cacaotero Nutrition 0.000 description 2
• 229940112129 campath Drugs 0.000 description 2
• 229950002826 canertinib Drugs 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 208000015114 central nervous system disease Diseases 0.000 description 2
• 201000007335 cerebellar astrocytoma Diseases 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 230000000973 chemotherapeutic effect Effects 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• 229960004630 chlorambucil Drugs 0.000 description 2
• 229940031301 claravis Drugs 0.000 description 2
• 238000011260 co-administration Methods 0.000 description 2
• 239000011248 coating agent Substances 0.000 description 2
• 235000012343 cottonseed oil Nutrition 0.000 description 2
• 239000002385 cottonseed oil Substances 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 238000006880 cross-coupling reaction Methods 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 2
• WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 150000004141 diterpene derivatives Chemical class 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 239000006196 drop Substances 0.000 description 2
• 229940075117 droxia Drugs 0.000 description 2
• 229940121647 egfr inhibitor Drugs 0.000 description 2
• 229940087477 ellence Drugs 0.000 description 2
• 229940073038 elspar Drugs 0.000 description 2
• 238000005538 encapsulation Methods 0.000 description 2
• 206010014599 encephalitis Diseases 0.000 description 2
• 201000002491 encephalomyelitis Diseases 0.000 description 2
• 229940007078 entamoeba histolytica Drugs 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 208000028104 epidemic louse-borne typhus Diseases 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 229930013356 epothilone Natural products 0.000 description 2
• 201000004101 esophageal cancer Diseases 0.000 description 2
• 239000000328 estrogen antagonist Substances 0.000 description 2
• 235000019441 ethanol Nutrition 0.000 description 2
• MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
• 229960000255 exemestane Drugs 0.000 description 2
• 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 2
• 208000002980 facial hemiatrophy Diseases 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
• 229960004039 finasteride Drugs 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 229960000390 fludarabine Drugs 0.000 description 2
• 229960005304 fludarabine phosphate Drugs 0.000 description 2
• 229960002074 flutamide Drugs 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 230000002538 fungal effect Effects 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 201000010175 gallbladder cancer Diseases 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 239000007903 gelatin capsule Substances 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 229960005277 gemcitabine Drugs 0.000 description 2
• 229960000578 gemtuzumab Drugs 0.000 description 2
• 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
• 201000011349 geniculate herpes zoster Diseases 0.000 description 2
• 201000007116 gestational trophoblastic neoplasm Diseases 0.000 description 2
• XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
• 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
• 201000009277 hairy cell leukemia Diseases 0.000 description 2
• 201000010536 head and neck cancer Diseases 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
• 229940003183 hexalen Drugs 0.000 description 2
• 125000006038 hexenyl group Chemical group 0.000 description 2
• 125000005980 hexynyl group Chemical group 0.000 description 2
• 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
• 239000003276 histone deacetylase inhibitor Substances 0.000 description 2
• 230000003054 hormonal effect Effects 0.000 description 2
• 102000048776 human CD274 Human genes 0.000 description 2
• 150000004677 hydrates Chemical class 0.000 description 2
• 229940096120 hydrea Drugs 0.000 description 2
• 229940090411 ifex Drugs 0.000 description 2
• 229960001101 ifosfamide Drugs 0.000 description 2
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
• 125000002632 imidazolidinyl group Chemical group 0.000 description 2
• 229960002751 imiquimod Drugs 0.000 description 2
• DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 230000003308 immunostimulating effect Effects 0.000 description 2
• 230000001024 immunotherapeutic effect Effects 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 201000004933 in situ carcinoma Diseases 0.000 description 2
• 238000000099 in vitro assay Methods 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 208000014674 injury Diseases 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 208000002551 irritable bowel syndrome Diseases 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• 210000004153 islets of langerhan Anatomy 0.000 description 2
• 125000001786 isothiazolyl group Chemical group 0.000 description 2
• 125000003965 isoxazolidinyl group Chemical group 0.000 description 2
• 125000000842 isoxazolyl group Chemical group 0.000 description 2
• FABUFPQFXZVHFB-PVYNADRNSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-PVYNADRNSA-N 0.000 description 2
• 201000008632 juvenile polyposis syndrome Diseases 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 210000000244 kidney pelvis Anatomy 0.000 description 2
• 208000004343 lateral medullary syndrome Diseases 0.000 description 2
• 201000010901 lateral sclerosis Diseases 0.000 description 2
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
• 229960003881 letrozole Drugs 0.000 description 2
• 229960004338 leuprorelin Drugs 0.000 description 2
• 229960001614 levamisole Drugs 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 210000000088 lip Anatomy 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 229960002247 lomustine Drugs 0.000 description 2
• 231100000515 lung injury Toxicity 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 229940124302 mTOR inhibitor Drugs 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 2
• 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
• 201000006512 mast cell neoplasm Diseases 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• 229940087732 matulane Drugs 0.000 description 2
• 229950008001 matuzumab Drugs 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 2
• 206010027191 meningioma Diseases 0.000 description 2
• 229960001428 mercaptopurine Drugs 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 2
• 210000004688 microtubule Anatomy 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 208000022499 mismatch repair cancer syndrome Diseases 0.000 description 2
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
• 230000000394 mitotic effect Effects 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 229950003968 motesanib Drugs 0.000 description 2
• RAHBGWKEPAQNFF-UHFFFAOYSA-N motesanib Chemical compound C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 RAHBGWKEPAQNFF-UHFFFAOYSA-N 0.000 description 2
• 229940124303 multikinase inhibitor Drugs 0.000 description 2
• 201000006938 muscular dystrophy Diseases 0.000 description 2
• 229940087004 mustargen Drugs 0.000 description 2
• 230000035772 mutation Effects 0.000 description 2
• 201000005962 mycosis fungoides Diseases 0.000 description 2
• 229940090009 myleran Drugs 0.000 description 2
• 208000010125 myocardial infarction Diseases 0.000 description 2
• 201000003631 narcolepsy Diseases 0.000 description 2
• 210000000581 natural killer T-cell Anatomy 0.000 description 2
• 210000005170 neoplastic cell Anatomy 0.000 description 2
• 210000000653 nervous system Anatomy 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
• 229960001346 nilotinib Drugs 0.000 description 2
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 2
• 229940109551 nipent Drugs 0.000 description 2
• 229950006344 nocodazole Drugs 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 201000002575 ocular melanoma Diseases 0.000 description 2
• 229960000572 olaparib Drugs 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 125000000160 oxazolidinyl group Chemical group 0.000 description 2
• 125000002971 oxazolyl group Chemical group 0.000 description 2
• 239000007800 oxidant agent Substances 0.000 description 2
• 230000036407 pain Effects 0.000 description 2
• 208000021090 palsy Diseases 0.000 description 2
• 201000010198 papillary carcinoma Diseases 0.000 description 2
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
• 229960003407 pegaptanib Drugs 0.000 description 2
• 108010001564 pegaspargase Proteins 0.000 description 2
• WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 2
• NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 description 2
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 2
• 125000005981 pentynyl group Chemical group 0.000 description 2
• 239000002304 perfume Substances 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 208000005026 persistent vegetative state Diseases 0.000 description 2
• 210000003800 pharynx Anatomy 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• 125000003386 piperidinyl group Chemical group 0.000 description 2
• 229960003171 plicamycin Drugs 0.000 description 2
• 231100000614 poison Toxicity 0.000 description 2
• 239000002574 poison Substances 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229960001131 ponatinib Drugs 0.000 description 2
• PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000000861 pro-apoptotic effect Effects 0.000 description 2
• 102000004196 processed proteins & peptides Human genes 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 229960004063 propylene glycol Drugs 0.000 description 2
• 125000003373 pyrazinyl group Chemical group 0.000 description 2
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
• 125000003226 pyrazolyl group Chemical group 0.000 description 2
• 125000002098 pyridazinyl group Chemical group 0.000 description 2
• 125000004076 pyridyl group Chemical group 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• 125000000168 pyrrolyl group Chemical group 0.000 description 2
• 229950001626 quizartinib Drugs 0.000 description 2
• CVWXJKQAOSCOAB-UHFFFAOYSA-N quizartinib Chemical compound O1C(C(C)(C)C)=CC(NC(=O)NC=2C=CC(=CC=2)C=2N=C3N(C4=CC=C(OCCN5CCOCC5)C=C4S3)C=2)=N1 CVWXJKQAOSCOAB-UHFFFAOYSA-N 0.000 description 2
• 108010077182 raf Kinases Proteins 0.000 description 2
• 102000009929 raf Kinases Human genes 0.000 description 2
• 229960004622 raloxifene Drugs 0.000 description 2
• 229960003876 ranibizumab Drugs 0.000 description 2
• 238000001953 recrystallisation Methods 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• 201000001275 rectum cancer Diseases 0.000 description 2
• 230000011514 reflex Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 201000010174 renal carcinoma Diseases 0.000 description 2
• 229950010550 resiquimod Drugs 0.000 description 2
• BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• 229940061969 rheumatrex Drugs 0.000 description 2
• 229960001302 ridaforolimus Drugs 0.000 description 2
• 229910052895 riebeckite Inorganic materials 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 229950009919 saracatinib Drugs 0.000 description 2
• OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 2
• 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
• 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
• BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 208000002477 septooptic dysplasia Diseases 0.000 description 2
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
• 235000012239 silicon dioxide Nutrition 0.000 description 2
• 210000004927 skin cell Anatomy 0.000 description 2
• 206010040882 skin lesion Diseases 0.000 description 2
• 231100000444 skin lesion Toxicity 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 239000012453 solvate Substances 0.000 description 2
• 229940034345 sotret Drugs 0.000 description 2
• 208000020431 spinal cord injury Diseases 0.000 description 2
• 208000002320 spinal muscular atrophy Diseases 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 229940068117 sprycel Drugs 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 229960001052 streptozocin Drugs 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 206010042772 syncope Diseases 0.000 description 2
• 229940095374 tabloid Drugs 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 229940099419 targretin Drugs 0.000 description 2
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
• 229940066453 tecentriq Drugs 0.000 description 2
• 229940061353 temodar Drugs 0.000 description 2
• 229960001278 teniposide Drugs 0.000 description 2
• 230000002381 testicular Effects 0.000 description 2
• 229960005353 testolactone Drugs 0.000 description 2
• BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 2
• 125000003831 tetrazolyl group Chemical group 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 125000000335 thiazolyl group Chemical group 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
• 229960005026 toremifene Drugs 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• 229940066958 treanda Drugs 0.000 description 2
• 229940111528 trexall Drugs 0.000 description 2
• 125000005310 triazolidinyl group Chemical group N1(NNCC1)* 0.000 description 2
• 125000001425 triazolyl group Chemical group 0.000 description 2
• 229940086984 trisenox Drugs 0.000 description 2
• 208000006961 tropical spastic paraparesis Diseases 0.000 description 2
• 206010061393 typhus Diseases 0.000 description 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• TUCIOBMMDDOEMM-RIYZIHGNSA-N tyrphostin B42 Chemical compound C1=C(O)C(O)=CC=C1\C=C(/C#N)C(=O)NCC1=CC=CC=C1 TUCIOBMMDDOEMM-RIYZIHGNSA-N 0.000 description 2
• 210000000626 ureter Anatomy 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 208000037965 uterine sarcoma Diseases 0.000 description 2
• ZOCKGBMQLCSHFP-KQRAQHLDSA-N valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 2
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
• 229950000578 vatalanib Drugs 0.000 description 2
• YTZALCGQUPRCGW-ZSFNYQMMSA-N verteporfin Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(CCC(=O)OC)=C(C)C(N3)=C3)=N2)C)=C(C=C)C(C)=C1C=C1C2=CC=C(C(=O)OC)[C@@H](C(=O)OC)[C@@]2(C)C3=N1 YTZALCGQUPRCGW-ZSFNYQMMSA-N 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 229940055760 yervoy Drugs 0.000 description 2
• 229940053890 zanosar Drugs 0.000 description 2
• FBDOJYYTMIHHDH-OZBJMMHXSA-N (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-2,4,6,8,10,14,20-heptaen-18-one Chemical compound CC[C@@]1(O)C(=O)OCC2=CN3Cc4cc5ccccc5nc4C3C=C12 FBDOJYYTMIHHDH-OZBJMMHXSA-N 0.000 description 1
• HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 1
• XTYSXGHMTNTKFH-BDEHJDMKSA-N (2s)-1-[(2s,4r)-4-benzyl-2-hydroxy-5-[[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]amino]-5-oxopentyl]-n-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;hydrate Chemical compound O.C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 XTYSXGHMTNTKFH-BDEHJDMKSA-N 0.000 description 1
• SVNJBEMPMKWDCO-KCHLEUMXSA-N (2s)-2-[[(2s)-3-carboxy-2-[[2-[[(2s)-5-(diaminomethylideneamino)-2-[[4-oxo-4-[[4-(4-oxo-8-phenylchromen-2-yl)morpholin-4-ium-4-yl]methoxy]butanoyl]amino]pentanoyl]amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoate Chemical compound C=1C(=O)C2=CC=CC(C=3C=CC=CC=3)=C2OC=1[N+]1(COC(=O)CCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C([O-])=O)CCOCC1 SVNJBEMPMKWDCO-KCHLEUMXSA-N 0.000 description 1
• REEGNIYAMZUTIO-MGSMBCBTSA-N (2s)-2-[[(3r)-3-decanoyloxytetradecanoyl]amino]-3-[(2r,3r,4r,5s,6r)-3-[[(3r)-3-decanoyloxytetradecanoyl]amino]-4-[(3r)-3-decanoyloxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid Chemical compound CCCCCCCCCCC[C@@H](OC(=O)CCCCCCCCC)CC(=O)N[C@H](C(O)=O)CO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCC)[C@H]1NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCC REEGNIYAMZUTIO-MGSMBCBTSA-N 0.000 description 1
• ICLAYQQKWJGHBV-XJZMHMBSSA-N (2s)-2-[[(3r)-3-decoxytetradecanoyl]amino]-3-[(2r,3r,4r,5s,6r)-3-[[(3r)-3-decoxytetradecanoyl]amino]-4-[(3r)-3-decoxytetradecanoyl]oxy-6-(hydroxymethyl)-5-phosphonooxyoxan-2-yl]oxypropanoic acid Chemical group CCCCCCCCCCC[C@@H](OCCCCCCCCCC)CC(=O)N[C@H](C(O)=O)CO[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OCCCCCCCCCC)[C@H]1NC(=O)C[C@@H](CCCCCCCCCCC)OCCCCCCCCCC ICLAYQQKWJGHBV-XJZMHMBSSA-N 0.000 description 1
• MHFUWOIXNMZFIW-WNQIDUERSA-N (2s)-2-hydroxypropanoic acid;n-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound C[C@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 MHFUWOIXNMZFIW-WNQIDUERSA-N 0.000 description 1
• YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 1
• VXPSARQTYDZXAO-CCHMMTNSSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O VXPSARQTYDZXAO-CCHMMTNSSA-N 0.000 description 1
• IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
• 125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
• 125000006728 (C1-C6) alkynyl group Chemical group 0.000 description 1
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 description 1
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• CTLOSZHDGZLOQE-UHFFFAOYSA-N 14-methoxy-9-[(4-methylpiperazin-1-yl)methyl]-9,19-diazapentacyclo[10.7.0.02,6.07,11.013,18]nonadeca-1(12),2(6),7(11),13(18),14,16-hexaene-8,10-dione Chemical compound O=C1C2=C3C=4C(OC)=CC=CC=4NC3=C3CCCC3=C2C(=O)N1CN1CCN(C)CC1 CTLOSZHDGZLOQE-UHFFFAOYSA-N 0.000 description 1
• NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical compound NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 description 1
• ROZCIVXTLACYNY-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)benzenesulfonamide Chemical compound C1=C(F)C(OC)=CC=C1NS(=O)(=O)C1=C(F)C(F)=C(F)C(F)=C1F ROZCIVXTLACYNY-UHFFFAOYSA-N 0.000 description 1
• UPAQRWMRKQCLSD-HTIIIDOHSA-N 2,3-dipalmitoyl-S-glycerylcysteine Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CSC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCC UPAQRWMRKQCLSD-HTIIIDOHSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
• FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
• VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3h-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
• XRXMNWGCKISMOH-UHFFFAOYSA-N 2-bromobenzoic acid Chemical class OC(=O)C1=CC=CC=C1Br XRXMNWGCKISMOH-UHFFFAOYSA-N 0.000 description 1
• CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical class OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• FFRFGVHNKJYNOV-DOVUUNBWSA-N 3',4'-Anhydrovinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C=C(C2)CC)N2CCC2=C1NC1=CC=CC=C21 FFRFGVHNKJYNOV-DOVUUNBWSA-N 0.000 description 1
• XDJCLCLBSGGNKS-UHFFFAOYSA-N 3-[3-[2-(1-piperidinyl)ethoxy]phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole Chemical compound C=1C=CC(C=2C3=CC(=CC=C3NN=2)C=2NN=CN=2)=CC=1OCCN1CCCCC1 XDJCLCLBSGGNKS-UHFFFAOYSA-N 0.000 description 1
• XRYJULCDUUATMC-CYBMUJFWSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 XRYJULCDUUATMC-CYBMUJFWSA-N 0.000 description 1
• SYYMNUFXRFAELA-BTQNPOSSSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol;hydrobromide Chemical compound Br.N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 SYYMNUFXRFAELA-BTQNPOSSSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-STUHELBRSA-N 4-amino-1-[(3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1C1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-STUHELBRSA-N 0.000 description 1
• WDAVVHQDPMVKOV-UHFFFAOYSA-N 4-fluoro-2-methyl-5-[(2-methyl-1h-pyrrol-3-yl)oxy]-1h-indole Chemical compound C=1C=C2NC(C)=CC2=C(F)C=1OC=1C=CNC=1C WDAVVHQDPMVKOV-UHFFFAOYSA-N 0.000 description 1
• SGOOQMRIPALTEL-UHFFFAOYSA-N 4-hydroxy-N,1-dimethyl-2-oxo-N-phenyl-3-quinolinecarboxamide Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
• MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 1
• 102100022464 5'-nucleotidase Human genes 0.000 description 1
• RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
• ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
• WTDWVLJJJOTABN-UHFFFAOYSA-N 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-n-methyl-1-benzofuran-3-carboxamide Chemical compound C1=C2C(C(=O)NC)=C(C=3C=CC(F)=CC=3)OC2=CC(N(CCO)S(C)(=O)=O)=C1C1CC1 WTDWVLJJJOTABN-UHFFFAOYSA-N 0.000 description 1
• ORVNHOYNEHYKJG-UHFFFAOYSA-N 8-(2,6-difluorophenyl)-2-(1,3-dihydroxypropan-2-ylamino)-4-(4-fluoro-2-methylphenyl)pyrido[2,3-d]pyrimidin-7-one Chemical compound CC1=CC(F)=CC=C1C1=NC(NC(CO)CO)=NC2=C1C=CC(=O)N2C1=C(F)C=CC=C1F ORVNHOYNEHYKJG-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
• 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 1
• GBJVVSCPOBPEIT-UHFFFAOYSA-N AZT-1152 Chemical compound N=1C=NC2=CC(OCCCN(CC)CCOP(O)(O)=O)=CC=C2C=1NC(=NN1)C=C1CC(=O)NC1=CC=CC(F)=C1 GBJVVSCPOBPEIT-UHFFFAOYSA-N 0.000 description 1
• 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
• 206010000599 Acromegaly Diseases 0.000 description 1
• 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
• 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
• 208000006888 Agnosia Diseases 0.000 description 1
• 241001047040 Agnosia Species 0.000 description 1
• 201000002882 Agraphia Diseases 0.000 description 1
• 208000024341 Aicardi syndrome Diseases 0.000 description 1
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
• UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
• 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 1
• 241001466460 Alveolata Species 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
• 241000224489 Amoeba Species 0.000 description 1
• 206010002027 Amyotrophy Diseases 0.000 description 1
• 208000009575 Angelman syndrome Diseases 0.000 description 1
• 206010002412 Angiocentric lymphomas Diseases 0.000 description 1
• 102400000068 Angiostatin Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 206010002660 Anoxia Diseases 0.000 description 1
• 241000976983 Anoxia Species 0.000 description 1
• 241000224482 Apicomplexa Species 0.000 description 1
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
• 206010073360 Appendix cancer Diseases 0.000 description 1
• 206010003062 Apraxia Diseases 0.000 description 1
• 101100452478 Arabidopsis thaliana DHAD gene Proteins 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 229940122815 Aromatase inhibitor Drugs 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 208000033116 Asbestos intoxication Diseases 0.000 description 1
• 208000036640 Asperger disease Diseases 0.000 description 1
• 201000006062 Asperger syndrome Diseases 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
• 102000014461 Ataxins Human genes 0.000 description 1
• 108010078286 Ataxins Proteins 0.000 description 1
• AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
• 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
• 206010003805 Autism Diseases 0.000 description 1
• 208000020706 Autistic disease Diseases 0.000 description 1
• 241000223836 Babesia Species 0.000 description 1
• 241000223840 Babesia bigemina Species 0.000 description 1
• 241000223838 Babesia bovis Species 0.000 description 1
• 208000008035 Back Pain Diseases 0.000 description 1
• 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
• 206010062804 Basal cell naevus syndrome Diseases 0.000 description 1
• 201000000046 Beckwith-Wiedemann syndrome Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 208000006373 Bell palsy Diseases 0.000 description 1
• 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
• 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
• 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
• 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 206010006074 Brachial plexus injury Diseases 0.000 description 1
• 208000004020 Brain Abscess Diseases 0.000 description 1
• 201000006474 Brain Ischemia Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• 244000056139 Brassica cretica Species 0.000 description 1
• 235000003351 Brassica cretica Nutrition 0.000 description 1
• 240000002791 Brassica napus Species 0.000 description 1
• 235000003343 Brassica rupestris Nutrition 0.000 description 1
• 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
• 206010006417 Bronchial carcinoma Diseases 0.000 description 1
• 206010006491 Brown-Sequard syndrome Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 206010006811 Bursitis Diseases 0.000 description 1
• 201000006883 CLOVES syndrome Diseases 0.000 description 1
• QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 208000022526 Canavan disease Diseases 0.000 description 1
• 241000222122 Candida albicans Species 0.000 description 1
• 239000005461 Canertinib Substances 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 206010007275 Carcinoid tumour Diseases 0.000 description 1
• 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
• 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
• 206010007558 Cardiac failure chronic Diseases 0.000 description 1
• 206010007559 Cardiac failure congestive Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 208000001387 Causalgia Diseases 0.000 description 1
• 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
• 206010064012 Central pain syndrome Diseases 0.000 description 1
• 206010008025 Cerebellar ataxia Diseases 0.000 description 1
• 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
• 206010008096 Cerebral atrophy Diseases 0.000 description 1
• 206010008120 Cerebral ischaemia Diseases 0.000 description 1
• 206010063094 Cerebral malaria Diseases 0.000 description 1
• 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
• 208000024699 Chagas disease Diseases 0.000 description 1
• 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 206010008513 Child maltreatment syndrome Diseases 0.000 description 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
• 102100039496 Choline transporter-like protein 4 Human genes 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 208000035865 Chronic mast cell leukemia Diseases 0.000 description 1
• VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
• 241000224483 Coccidia Species 0.000 description 1
• 241000223205 Coccidioides immitis Species 0.000 description 1
• 208000010200 Cockayne syndrome Diseases 0.000 description 1
• 208000001353 Coffin-Lowry syndrome Diseases 0.000 description 1
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
• 206010071161 Colon dysplasia Diseases 0.000 description 1
• 208000019399 Colonic disease Diseases 0.000 description 1
• 206010010071 Coma Diseases 0.000 description 1
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 208000029323 Congenital myotonia Diseases 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 208000012609 Cowden disease Diseases 0.000 description 1
• 201000002847 Cowden syndrome Diseases 0.000 description 1
• 108091029430 CpG site Proteins 0.000 description 1
• 208000009283 Craniosynostoses Diseases 0.000 description 1
• 206010049889 Craniosynostosis Diseases 0.000 description 1
• 241000222718 Crithidia fasciculata Species 0.000 description 1
• 244000124209 Crocus sativus Species 0.000 description 1
• 235000015655 Crocus sativus Nutrition 0.000 description 1
• 229930188224 Cryptophycin Natural products 0.000 description 1
• 241000223936 Cryptosporidium parvum Species 0.000 description 1
• 208000012514 Cumulative Trauma disease Diseases 0.000 description 1
• 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 description 1
• 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 1
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
• 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
• 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
• 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
• 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
• 206010011732 Cyst Diseases 0.000 description 1
• 201000005171 Cystadenoma Diseases 0.000 description 1
• 241000205707 Cystoisospora belli Species 0.000 description 1
• UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
• 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• GUGHGUXZJWAIAS-QQYBVWGSSA-N Daunorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GUGHGUXZJWAIAS-QQYBVWGSSA-N 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
• BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
• 108010016626 Dipeptides Proteins 0.000 description 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
• 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 description 1
• 206010071545 Early infantile epileptic encephalopathy with burst-suppression Diseases 0.000 description 1
• XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
• 241000223924 Eimeria Species 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
• 208000002403 Encephalocele Diseases 0.000 description 1
• 208000032274 Encephalopathy Diseases 0.000 description 1
• 108010079505 Endostatins Proteins 0.000 description 1
• 206010014824 Endotoxic shock Diseases 0.000 description 1
• 241000588914 Enterobacter Species 0.000 description 1
• 241000194032 Enterococcus faecalis Species 0.000 description 1
• 241000194031 Enterococcus faecium Species 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 241000588698 Erwinia Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 208000024720 Fabry Disease Diseases 0.000 description 1
• 206010063006 Facial spasm Diseases 0.000 description 1
• 208000002091 Febrile Seizures Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 201000009128 Flinders Island spotted fever Diseases 0.000 description 1
• 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
• 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 208000007882 Gastritis Diseases 0.000 description 1
• 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
• 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
• 208000015872 Gaucher disease Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 239000001828 Gelatine Substances 0.000 description 1
• 102000013404 Geranyltranstransferase Human genes 0.000 description 1
• 108010026318 Geranyltranstransferase Proteins 0.000 description 1
• 208000007223 Gerstmann syndrome Diseases 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 208000031995 Gorlin syndrome Diseases 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 208000009396 Group II Malformations of Cortical Development Diseases 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 229940124683 HCV polymerase inhibitor Drugs 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 208000031797 Harlequin ichthyosis Diseases 0.000 description 1
• 241000193159 Hathewaya histolytica Species 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 206010019233 Headaches Diseases 0.000 description 1
• 208000004095 Hemifacial Spasm Diseases 0.000 description 1
• 208000019037 Hemihyperplasia-multiple lipomatosis syndrome Diseases 0.000 description 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
• 206010073069 Hepatic cancer Diseases 0.000 description 1
• 206010019668 Hepatic fibrosis Diseases 0.000 description 1
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
• 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 206010019909 Hernia Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 241000228402 Histoplasma Species 0.000 description 1
• 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
• 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
• 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
• 101100407305 Homo sapiens CD274 gene Proteins 0.000 description 1
• 101000889282 Homo sapiens Choline transporter-like protein 4 Proteins 0.000 description 1
• 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 description 1
• 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
• 101100407307 Homo sapiens PDCD1LG2 gene Proteins 0.000 description 1
• 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
• 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
• 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
• 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 208000037171 Hypercorticoidism Diseases 0.000 description 1
• 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
• 208000021710 Hyperpigmentation disease Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 208000013016 Hypoglycemia Diseases 0.000 description 1
• 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• 101150057269 IKBKB gene Proteins 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
• JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 206010021639 Incontinence Diseases 0.000 description 1
• 208000007031 Incontinentia pigmenti Diseases 0.000 description 1
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
• 208000035899 Infantile spasms syndrome Diseases 0.000 description 1
• 206010061216 Infarction Diseases 0.000 description 1
• 206010022158 Injury to brachial plexus due to birth trauma Diseases 0.000 description 1
• 108030003815 Inositol 3-kinases Proteins 0.000 description 1
• IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
• 102100029843 Interferon regulatory factor 3 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 208000018650 Intervertebral disc disease Diseases 0.000 description 1
• 201000008450 Intracranial aneurysm Diseases 0.000 description 1
• 206010022773 Intracranial pressure increased Diseases 0.000 description 1
• 208000000209 Isaacs syndrome Diseases 0.000 description 1
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
• 241000567229 Isospora Species 0.000 description 1
• 201000008645 Joubert syndrome Diseases 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• 108010038142 KAI 9803 Proteins 0.000 description 1
• 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
• 206010023347 Keratoacanthoma Diseases 0.000 description 1
• 241000588747 Klebsiella pneumoniae Species 0.000 description 1
• 208000006541 Klippel-Feil syndrome Diseases 0.000 description 1
• 208000000588 Klippel-Trenaunay-Weber Syndrome Diseases 0.000 description 1
• 208000034642 Klippel-Trénaunay syndrome Diseases 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 102000017578 LAG3 Human genes 0.000 description 1
• 208000005101 LEOPARD Syndrome Diseases 0.000 description 1
• 208000005870 Lafora disease Diseases 0.000 description 1
• 208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 1
• 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
• 208000001913 Lamellar ichthyosis Diseases 0.000 description 1
• 239000004166 Lanolin Substances 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 208000006136 Leigh Disease Diseases 0.000 description 1
• 208000017507 Leigh syndrome Diseases 0.000 description 1
• 241000222722 Leishmania <genus> Species 0.000 description 1
• 241000222734 Leishmania mexicana Species 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
• 208000009829 Lewy Body Disease Diseases 0.000 description 1
• 201000002832 Lewy body dementia Diseases 0.000 description 1
• 206010048911 Lissencephaly Diseases 0.000 description 1
• 241000186779 Listeria monocytogenes Species 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 206010025386 Macrodactyly Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
• 206010025537 Malignant anorectal neoplasms Diseases 0.000 description 1
• 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 description 1
• 208000032271 Malignant tumor of penis Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 206010026865 Mass Diseases 0.000 description 1
• 201000002571 Melkersson-Rosenthal syndrome Diseases 0.000 description 1
• 208000027530 Meniere disease Diseases 0.000 description 1
• 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
• 208000012583 Menkes disease Diseases 0.000 description 1
• 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
• 108010052006 Mitogen Receptors Proteins 0.000 description 1
• 102000018656 Mitogen Receptors Human genes 0.000 description 1
• 229940121849 Mitotic inhibitor Drugs 0.000 description 1
• 206010027802 Moebius II syndrome Diseases 0.000 description 1
• 208000034167 Moebius syndrome Diseases 0.000 description 1
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
• 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 1
• 206010069681 Monomelic amyotrophy Diseases 0.000 description 1
• 208000016285 Movement disease Diseases 0.000 description 1
• 208000009433 Moyamoya Disease Diseases 0.000 description 1
• 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
• 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
• 206010062901 Multiple lentigines syndrome Diseases 0.000 description 1
• MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000008238 Muscle Spasticity Diseases 0.000 description 1
• 206010028289 Muscle atrophy Diseases 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 206010028424 Myasthenic syndrome Diseases 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
• 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
• 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
• 208000002033 Myoclonus Diseases 0.000 description 1
• 201000004458 Myoma Diseases 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
• 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
• 102000012064 NLR Proteins Human genes 0.000 description 1
• 108091005686 NOD-like receptors Proteins 0.000 description 1
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 241001212279 Neisseriales Species 0.000 description 1
• 206010052057 Neuroborreliosis Diseases 0.000 description 1
• 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
• 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
• 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
• 206010072359 Neuromyotonia Diseases 0.000 description 1
• 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 1
• 101800001020 Non-structural protein 4A Proteins 0.000 description 1
• 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 description 1
• 208000020265 O'Sullivan-McLeod syndrome Diseases 0.000 description 1
• 208000011623 Obstructive Lung disease Diseases 0.000 description 1
• 206010068106 Occipital neuralgia Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 208000001388 Opportunistic Infections Diseases 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
• 206010069350 Osmotic demyelination syndrome Diseases 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
• 208000012868 Overgrowth Diseases 0.000 description 1
• 229940124060 PD-1 antagonist Drugs 0.000 description 1
• 239000012270 PD-1 inhibitor Substances 0.000 description 1
• 239000012668 PD-1-inhibitor Substances 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 206010034299 Penile cancer Diseases 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108010013639 Peptidoglycan Proteins 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
• 206010034811 Pharyngeal cancer Diseases 0.000 description 1
• 241000286209 Phasianidae Species 0.000 description 1
• IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
• 206010050487 Pinealoblastoma Diseases 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
• 235000011613 Pinus brutia Nutrition 0.000 description 1
• 241000018646 Pinus brutia Species 0.000 description 1
• 208000007452 Plasmacytoma Diseases 0.000 description 1
• 241000223960 Plasmodium falciparum Species 0.000 description 1
• 241000223821 Plasmodium malariae Species 0.000 description 1
• 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
• 241001505293 Plasmodium ovale Species 0.000 description 1
• 241000223810 Plasmodium vivax Species 0.000 description 1
• 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
• 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
• 241000233872 Pneumocystis carinii Species 0.000 description 1
• 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
• 239000004952 Polyamide Substances 0.000 description 1
• 208000008601 Polycythemia Diseases 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 206010036172 Porencephaly Diseases 0.000 description 1
• 108010013381 Porins Proteins 0.000 description 1
• 102000017033 Porins Human genes 0.000 description 1
• 206010071366 Post-traumatic neck syndrome Diseases 0.000 description 1
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
• 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
• 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
• HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
• 208000037276 Primitive Peripheral Neuroectodermal Tumors Diseases 0.000 description 1
• 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
• 102100030090 Probable ATP-dependent RNA helicase DHX58 Human genes 0.000 description 1
• 102000011195 Profilin Human genes 0.000 description 1
• 108050001408 Profilin Proteins 0.000 description 1
• 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
• 101710094000 Programmed cell death 1 ligand 1 Proteins 0.000 description 1
• 208000012287 Prolapse Diseases 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
• 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 206010037731 Queensland tick typhus Diseases 0.000 description 1
• 102000014128 RANK Ligand Human genes 0.000 description 1
• 108010025832 RANK Ligand Proteins 0.000 description 1
• 108091005685 RIG-I-like receptors Proteins 0.000 description 1
• 208000032831 Ramsay Hunt syndrome Diseases 0.000 description 1
• 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
• 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
• 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
• 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
• 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 208000005793 Restless legs syndrome Diseases 0.000 description 1
• 208000006289 Rett Syndrome Diseases 0.000 description 1
• 201000007981 Reye syndrome Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
• 241000606701 Rickettsia Species 0.000 description 1
• 241001495403 Rickettsia africae Species 0.000 description 1
• 241000606699 Rickettsia conorii Species 0.000 description 1
• 241000147135 Rickettsia felis Species 0.000 description 1
• 241000606697 Rickettsia prowazekii Species 0.000 description 1
• 241000606695 Rickettsia rickettsii Species 0.000 description 1
• 241000606726 Rickettsia typhi Species 0.000 description 1
• NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
• 108010038122 S-(2,3-bis(palmitoyloxy)propyl)cysteine Proteins 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 208000021811 Sandhoff disease Diseases 0.000 description 1
• 241000224003 Sarcocystis Species 0.000 description 1
• 206010039484 Sarcocystis infections Diseases 0.000 description 1
• 241001473628 Sarcocystis suihominis Species 0.000 description 1
• 208000006775 Sarcocystosis Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 208000033995 Septo-optic dysplasia spectrum Diseases 0.000 description 1
• 229940121742 Serine/threonine kinase inhibitor Drugs 0.000 description 1
• 244000000231 Sesamum indicum Species 0.000 description 1
• 235000003434 Sesamum indicum Nutrition 0.000 description 1
• 208000002108 Shaken Baby Syndrome Diseases 0.000 description 1
• 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 206010064387 Sotos' syndrome Diseases 0.000 description 1
• 206010041415 Spastic paralysis Diseases 0.000 description 1
• 201000010829 Spina bifida Diseases 0.000 description 1
• 208000006097 Spinal Dysraphism Diseases 0.000 description 1
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
• 241000191963 Staphylococcus epidermidis Species 0.000 description 1
• XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
• 208000007107 Stomach Ulcer Diseases 0.000 description 1
• 241000193998 Streptococcus pneumoniae Species 0.000 description 1
• 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
• 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
• 238000006069 Suzuki reaction reaction Methods 0.000 description 1
• 206010042928 Syringomyelia Diseases 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 201000008736 Systemic mastocytosis Diseases 0.000 description 1
• 230000006044 T cell activation Effects 0.000 description 1
• 229940126530 T cell activator Drugs 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 108091005735 TGF-beta receptors Proteins 0.000 description 1
• 241001523006 Talaromyces marneffei Species 0.000 description 1
• 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
• 208000034799 Tauopathies Diseases 0.000 description 1
• 208000022292 Tay-Sachs disease Diseases 0.000 description 1
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
• 208000000491 Tendinopathy Diseases 0.000 description 1
• 206010043255 Tendonitis Diseases 0.000 description 1
• 208000004760 Tenosynovitis Diseases 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 241000223777 Theileria Species 0.000 description 1
• 241000223779 Theileria parva Species 0.000 description 1
• 206010043515 Throat cancer Diseases 0.000 description 1
• 208000005485 Thrombocytosis Diseases 0.000 description 1
• 201000009365 Thymic carcinoma Diseases 0.000 description 1
• 208000033781 Thyroid carcinoma Diseases 0.000 description 1
• SUJUHGSWHZTSEU-UHFFFAOYSA-N Tipranavir Natural products C1C(O)=C(C(CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)C(=O)OC1(CCC)CCC1=CC=CC=C1 SUJUHGSWHZTSEU-UHFFFAOYSA-N 0.000 description 1
• 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
• 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
• 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
• 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
• 206010062129 Tongue neoplasm Diseases 0.000 description 1
• 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
• IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
• 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
• 208000000323 Tourette Syndrome Diseases 0.000 description 1
• 208000016620 Tourette disease Diseases 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 231100000076 Toxic encephalopathy Toxicity 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• 241000223997 Toxoplasma gondii Species 0.000 description 1
• 201000005485 Toxoplasmosis Diseases 0.000 description 1
• 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
• 208000032109 Transient ischaemic attack Diseases 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• 206010044565 Tremor Diseases 0.000 description 1
• 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
• 206010044696 Tropical spastic paresis Diseases 0.000 description 1
• 241000223104 Trypanosoma Species 0.000 description 1
• 241000224557 Trypanosoma brucei brucei Species 0.000 description 1
• 241001442399 Trypanosoma brucei gambiense Species 0.000 description 1
• 241001442397 Trypanosoma brucei rhodesiense Species 0.000 description 1
• 241000223107 Trypanosoma congolense Species 0.000 description 1
• 241000223099 Trypanosoma vivax Species 0.000 description 1
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
• 102000014384 Type C Phospholipases Human genes 0.000 description 1
• 108010079194 Type C Phospholipases Proteins 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
• 206010046431 Urethral cancer Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
• 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
• 208000024248 Vascular System injury Diseases 0.000 description 1
• 206010063661 Vascular encephalopathy Diseases 0.000 description 1
• 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
• 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
• 208000012339 Vascular injury Diseases 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• XXUSUMBPMCGKSK-DXNYSGJVSA-N Vinoxine Natural products COC(=O)C1C2CC(N(CCO)C/C/2=C/C)c3cc4ccccc4n13 XXUSUMBPMCGKSK-DXNYSGJVSA-N 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 208000013058 Weber syndrome Diseases 0.000 description 1
• 108010046377 Whey Proteins Proteins 0.000 description 1
• 208000021567 Whiplash injury Diseases 0.000 description 1
• 206010049644 Williams syndrome Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 241000589634 Xanthomonas Species 0.000 description 1
• 229910052769 Ytterbium Inorganic materials 0.000 description 1
• WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 201000004525 Zellweger Syndrome Diseases 0.000 description 1
• 208000036813 Zellweger spectrum disease Diseases 0.000 description 1
• 229920000392 Zymosan Polymers 0.000 description 1
• 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
• RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 description 1
• IBHARWXWOCPXCR-WELGVCPWSA-N [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl (2-decoxy-3-dodecylsulfanylpropyl) hydrogen phosphate Chemical compound C1[C@H](N=[N+]=[N-])[C@@H](COP(O)(=O)OCC(CSCCCCCCCCCCCC)OCCCCCCCCCC)O[C@H]1N1C(=O)NC(=O)C(C)=C1 IBHARWXWOCPXCR-WELGVCPWSA-N 0.000 description 1
• 229960004748 abacavir Drugs 0.000 description 1
• MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
• 229960004103 abiraterone acetate Drugs 0.000 description 1
• UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 229940028652 abraxane Drugs 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 229960004150 aciclovir Drugs 0.000 description 1
• 239000003377 acid catalyst Substances 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000006336 acinar cell carcinoma Diseases 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
• 208000005298 acute pain Diseases 0.000 description 1
• 108091005764 adaptor proteins Proteins 0.000 description 1
• 102000035181 adaptor proteins Human genes 0.000 description 1
• 229960001997 adefovir Drugs 0.000 description 1
• 229960003205 adefovir dipivoxil Drugs 0.000 description 1
• 208000021096 adenomatous colon polyp Diseases 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 201000005188 adrenal gland cancer Diseases 0.000 description 1
• 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 229940064305 adrucil Drugs 0.000 description 1
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 229940042992 afinitor Drugs 0.000 description 1
• QNAYBMKLOCPYGJ-UHFFFAOYSA-M alaninate Chemical compound CC(N)C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-M 0.000 description 1
• 229960005310 aldesleukin Drugs 0.000 description 1
• 229940110282 alimta Drugs 0.000 description 1
• 229960001445 alitretinoin Drugs 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 229950004424 alovudine Drugs 0.000 description 1
• 208000011916 alternating hemiplegia Diseases 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
• VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 229950005846 amdoxovir Drugs 0.000 description 1
• 229960001097 amifostine Drugs 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 229960001830 amprenavir Drugs 0.000 description 1
• YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
• 201000007696 anal canal cancer Diseases 0.000 description 1
• 229940004511 androxy Drugs 0.000 description 1
• 206010002320 anencephaly Diseases 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 208000000252 angiomatosis Diseases 0.000 description 1
• 208000012948 angioosteohypertrophic syndrome Diseases 0.000 description 1
• 229950001104 anhydrovinblastine Drugs 0.000 description 1
• 230000007953 anoxia Effects 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 239000002260 anti-inflammatory agent Substances 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 238000011861 anti-inflammatory therapy Methods 0.000 description 1
• 230000002927 anti-mitotic effect Effects 0.000 description 1
• 230000003064 anti-oxidating effect Effects 0.000 description 1
• 230000000692 anti-sense effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 230000005809 anti-tumor immunity Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 201000007201 aphasia Diseases 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 208000021780 appendiceal neoplasm Diseases 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 206010003074 arachnoiditis Diseases 0.000 description 1
• 229940078010 arimidex Drugs 0.000 description 1
• 229940087620 aromasin Drugs 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 206010003441 asbestosis Diseases 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 229960003277 atazanavir Drugs 0.000 description 1
• AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 230000002238 attenuated effect Effects 0.000 description 1
• 108010044540 auristatin Proteins 0.000 description 1
• 210000003403 autonomic nervous system Anatomy 0.000 description 1
• 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
• 208000031375 autosomal dominant myotonia congenita Diseases 0.000 description 1
• 201000001286 autosomal recessive congenital ichthyosis 4B Diseases 0.000 description 1
• 229960003005 axitinib Drugs 0.000 description 1
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 201000008680 babesiosis Diseases 0.000 description 1
• 244000052616 bacterial pathogen Species 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 235000012216 bentonite Nutrition 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
• 201000001531 bladder carcinoma Diseases 0.000 description 1
• UBJAHGAUPNGZFF-XOVTVWCYSA-N bms-184476 Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OCSC)C(=O)C1=CC=CC=C1 UBJAHGAUPNGZFF-XOVTVWCYSA-N 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
• 201000006431 brachial plexus neuropathy Diseases 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 208000021138 brain aneurysm Diseases 0.000 description 1
• 208000030224 brain astrocytoma Diseases 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 201000007293 brain stem infarction Diseases 0.000 description 1
• 235000008429 bread Nutrition 0.000 description 1
• JORVRJNILJXMMG-OLNQLETPSA-N brecanavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=C2OCOC2=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C(C=C1)=CC=C1OCC1=CSC(C)=N1 JORVRJNILJXMMG-OLNQLETPSA-N 0.000 description 1
• 229950009079 brecanavir Drugs 0.000 description 1
• 230000031709 bromination Effects 0.000 description 1
• 238000005893 bromination reaction Methods 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 201000002143 bronchus adenoma Diseases 0.000 description 1
• 229940112133 busulfex Drugs 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• PKFDLKSEZWEFGL-MHARETSRSA-N c-di-GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=C(C(NC(N)=N5)=O)N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 PKFDLKSEZWEFGL-MHARETSRSA-N 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 235000012241 calcium silicate Nutrition 0.000 description 1
• 229940088954 camptosar Drugs 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 229940095731 candida albicans Drugs 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 208000025046 carcinoma of lip Diseases 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 229920002301 cellulose acetate Polymers 0.000 description 1
• 229940121420 cemiplimab Drugs 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 208000009885 central pontine myelinolysis Diseases 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 208000030239 cerebral astrocytoma Diseases 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 206010008129 cerebral palsy Diseases 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 description 1
• 125000003636 chemical group Chemical group 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 201000002797 childhood leukemia Diseases 0.000 description 1
• 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
• 208000012191 childhood neoplasm Diseases 0.000 description 1
• 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 208000020832 chronic kidney disease Diseases 0.000 description 1
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
• 101150116749 chuk gene Proteins 0.000 description 1
• OHNBIIZWIUBGTK-NYPSMHOZSA-N cid_23581792 Chemical compound O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 OHNBIIZWIUBGTK-NYPSMHOZSA-N 0.000 description 1
• 229960000724 cidofovir Drugs 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• PJZPDFUUXKKDNB-KNINVFKUSA-N ciluprevir Chemical compound N([C@@H]1C(=O)N2[C@H](C(N[C@@]3(C[C@H]3\C=C/CCCCC1)C(O)=O)=O)C[C@H](C2)OC=1C2=CC=C(C=C2N=C(C=1)C=1N=C(NC(C)C)SC=1)OC)C(=O)OC1CCCC1 PJZPDFUUXKKDNB-KNINVFKUSA-N 0.000 description 1
• 229940060799 clarus Drugs 0.000 description 1
• WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
• 229940103380 clolar Drugs 0.000 description 1
• 229940126523 co-drug Drugs 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 239000002285 corn oil Substances 0.000 description 1
• 235000005687 corn oil Nutrition 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 210000000877 corpus callosum Anatomy 0.000 description 1
• 210000003792 cranial nerve Anatomy 0.000 description 1
• 108010006226 cryptophycin Proteins 0.000 description 1
• PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
• PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 230000001186 cumulative effect Effects 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
• 229960000978 cyproterone acetate Drugs 0.000 description 1
• UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 239000002254 cytotoxic agent Substances 0.000 description 1
• 231100000599 cytotoxic agent Toxicity 0.000 description 1
• 229940059359 dacogen Drugs 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 229960002272 degarelix Drugs 0.000 description 1
• 229960005319 delavirdine Drugs 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 229960002923 denileukin diftitox Drugs 0.000 description 1
• 108010017271 denileukin diftitox Proteins 0.000 description 1
• 229960001251 denosumab Drugs 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 230000002074 deregulated effect Effects 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 229960002656 didanosine Drugs 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• OAIHMBRTKDWZQG-WFVUJJAZSA-L disodium;[(8r,9s,13s,14s,17s)-3-[bis(2-chloroethyl)carbamoyloxy]-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] phosphate;hydrate Chemical compound O.[Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 OAIHMBRTKDWZQG-WFVUJJAZSA-L 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
• AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
• 229930188854 dolastatin Natural products 0.000 description 1
• 238000003182 dose-response assay Methods 0.000 description 1
• 229940115080 doxil Drugs 0.000 description 1
• 229950004203 droloxifene Drugs 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 230000036267 drug metabolism Effects 0.000 description 1
• 238000002651 drug therapy Methods 0.000 description 1
• JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
• 229960004199 dutasteride Drugs 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 208000019479 dysautonomia Diseases 0.000 description 1
• 208000001848 dysentery Diseases 0.000 description 1
• 206010058319 dysgraphia Diseases 0.000 description 1
• 206010013932 dyslexia Diseases 0.000 description 1
• 201000006549 dyspepsia Diseases 0.000 description 1
• 208000010118 dystonia Diseases 0.000 description 1
• 239000003221 ear drop Substances 0.000 description 1
• 229940047652 ear drops Drugs 0.000 description 1
• 229960002224 eculizumab Drugs 0.000 description 1
• 229960003804 efavirenz Drugs 0.000 description 1
• XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 239000012039 electrophile Substances 0.000 description 1
• 229940120655 eloxatin Drugs 0.000 description 1
• 229940000733 emcyt Drugs 0.000 description 1
• 229960000366 emtricitabine Drugs 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 229940032049 enterococcus faecalis Drugs 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 229960004671 enzalutamide Drugs 0.000 description 1
• WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
• 238000007824 enzymatic assay Methods 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 229940125532 enzyme inhibitor Drugs 0.000 description 1
• 229950006370 epacadostat Drugs 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 230000001037 epileptic effect Effects 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
• 150000003883 epothilone derivatives Chemical class 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 201000006517 essential tremor Diseases 0.000 description 1
• ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
• 229960004750 estramustine phosphate Drugs 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 235000019439 ethyl acetate Nutrition 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• XXBDOTXPQDVHIP-JTQLQIEISA-N ethyl n-[(2s)-5-amino-2-methyl-3-phenyl-1,2-dihydropyrido[3,4-b]pyrazin-7-yl]carbamate Chemical compound C=1([C@H](C)NC=2C=C(N=C(N)C=2N=1)NC(=O)OCC)C1=CC=CC=C1 XXBDOTXPQDVHIP-JTQLQIEISA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 229940098617 ethyol Drugs 0.000 description 1
• LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
• 229960000752 etoposide phosphate Drugs 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 229960005167 everolimus Drugs 0.000 description 1
• 229940085363 evista Drugs 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 239000003885 eye ointment Substances 0.000 description 1
• 229960004396 famciclovir Drugs 0.000 description 1
• GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
• 208000020603 familial colorectal cancer Diseases 0.000 description 1
• 229940043168 fareston Drugs 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 229940087476 femara Drugs 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 229940002006 firmagon Drugs 0.000 description 1
• 210000003495 flagella Anatomy 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 238000000198 fluorescence anisotropy Methods 0.000 description 1
• 229960001751 fluoxymesterone Drugs 0.000 description 1
• 229960003142 fosamprenavir Drugs 0.000 description 1
• MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 229960002258 fulvestrant Drugs 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 208000024386 fungal infectious disease Diseases 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 201000007487 gallbladder carcinoma Diseases 0.000 description 1
• 229960002963 ganciclovir Drugs 0.000 description 1
• 208000010749 gastric carcinoma Diseases 0.000 description 1
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
• 229960002584 gefitinib Drugs 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229940020967 gemzar Drugs 0.000 description 1
• 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229940084910 gliadel Drugs 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
• 229960002913 goserelin Drugs 0.000 description 1
• 229960003690 goserelin acetate Drugs 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 210000005255 gram-positive cell Anatomy 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 101150098203 grb2 gene Proteins 0.000 description 1
• SCMLRESZJCKCTC-KMYQRJGFSA-N gtpl8173 Chemical compound C12=CC=C(CSCC)C=C2C2=C(CNC3=O)C3=C3C4=CC(CSCC)=CC=C4N4C3=C2N1[C@]1(C)[C@@](O)(C(=O)OC)C[C@H]4O1 SCMLRESZJCKCTC-KMYQRJGFSA-N 0.000 description 1
• 210000002768 hair cell Anatomy 0.000 description 1
• 229940083461 halotestin Drugs 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
• 231100000869 headache Toxicity 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 208000024798 heartburn Diseases 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
• 208000029824 high grade glioma Diseases 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 239000004030 hiv protease inhibitor Substances 0.000 description 1
• 208000009624 holoprosencephaly Diseases 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 229940088013 hycamtin Drugs 0.000 description 1
• 201000009075 hydranencephaly Diseases 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 150000002430 hydrocarbons Chemical class 0.000 description 1
• 150000004680 hydrogen peroxides Chemical class 0.000 description 1
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
• 208000013403 hyperactivity Diseases 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 230000002218 hypoglycaemic effect Effects 0.000 description 1
• 208000013010 hypopharyngeal carcinoma Diseases 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 229940099279 idamycin Drugs 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• 230000005934 immune activation Effects 0.000 description 1
• 230000005965 immune activity Effects 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 230000001506 immunosuppresive effect Effects 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 201000008319 inclusion body myositis Diseases 0.000 description 1
• 229960001936 indinavir Drugs 0.000 description 1
• 230000007574 infarction Effects 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 230000015788 innate immune response Effects 0.000 description 1
• 229960000367 inositol Drugs 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 229960003521 interferon alfa-2a Drugs 0.000 description 1
• 229960003507 interferon alfa-2b Drugs 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 229940028885 interleukin-4 Drugs 0.000 description 1
• 201000002313 intestinal cancer Diseases 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
• 201000009941 intracranial hypertension Diseases 0.000 description 1
• 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 229940065638 intron a Drugs 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229940084651 iressa Drugs 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 229950000886 isetionate Drugs 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 229960002014 ixabepilone Drugs 0.000 description 1
• 229940111707 ixempra Drugs 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 1
• 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
• 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 1
• WXNQMDPKECZMAO-ASGAITCASA-N kai9803 Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC[C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=C(O)C=C1 WXNQMDPKECZMAO-ASGAITCASA-N 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 206010023497 kuru Diseases 0.000 description 1
• 229960001627 lamivudine Drugs 0.000 description 1
• JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
• 229940039717 lanolin Drugs 0.000 description 1
• 235000019388 lanolin Nutrition 0.000 description 1
• 229960001320 lapatinib ditosylate Drugs 0.000 description 1
• 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 201000005264 laryngeal carcinoma Diseases 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 229950004697 lasinavir Drugs 0.000 description 1
• 201000003723 learning disability Diseases 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 229960004942 lenalidomide Drugs 0.000 description 1
• 231100000636 lethal dose Toxicity 0.000 description 1
• 229940063725 leukeran Drugs 0.000 description 1
• 208000036546 leukodystrophy Diseases 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 238000005339 levitation Methods 0.000 description 1
• 210000004558 lewy body Anatomy 0.000 description 1
• UGFHIPBXIWJXNA-UHFFFAOYSA-N liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
• 229950007056 liarozole Drugs 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 208000014817 lissencephaly spectrum disease Diseases 0.000 description 1
• 229940115931 listeria monocytogenes Drugs 0.000 description 1
• 201000002250 liver carcinoma Diseases 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 229960003538 lonidamine Drugs 0.000 description 1
• WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
• 229960004844 lovastatin Drugs 0.000 description 1
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
• CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 1
• 229950005634 loxoribine Drugs 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 201000001037 lung lymphoma Diseases 0.000 description 1
• 108010078259 luprolide acetate gel depot Proteins 0.000 description 1
• 229940087857 lupron Drugs 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 208000006116 lymphomatoid granulomatosis Diseases 0.000 description 1
• 230000001589 lymphoproliferative effect Effects 0.000 description 1
• 229940100352 lynparza Drugs 0.000 description 1
• 229940100029 lysodren Drugs 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 108010051618 macrophage stimulatory lipopeptide 2 Proteins 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
• 239000000347 magnesium hydroxide Substances 0.000 description 1
• 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
• 239000000391 magnesium silicate Substances 0.000 description 1
• 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
• 235000019793 magnesium trisilicate Nutrition 0.000 description 1
• 229940099273 magnesium trisilicate Drugs 0.000 description 1
• 230000036244 malformation Effects 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 208000030883 malignant astrocytoma Diseases 0.000 description 1
• 208000029565 malignant colon neoplasm Diseases 0.000 description 1
• 201000011614 malignant glioma Diseases 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 229960004616 medroxyprogesterone Drugs 0.000 description 1
• 229940090004 megace Drugs 0.000 description 1
• 229960001786 megestrol Drugs 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 210000000716 merkel cell Anatomy 0.000 description 1
• 229960004635 mesna Drugs 0.000 description 1
• 229940101533 mesnex Drugs 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 208000004141 microcephaly Diseases 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 229950011535 mivobulin Drugs 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• ZDZOTLJHXYCWBA-BSEPLHNVSA-N molport-006-823-826 Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-BSEPLHNVSA-N 0.000 description 1
• 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• 150000004712 monophosphates Chemical class 0.000 description 1
• 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
• 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
• 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
• BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
• 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
• 201000000585 muscular atrophy Diseases 0.000 description 1
• 235000010460 mustard Nutrition 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 208000017869 myelodysplastic/myeloproliferative disease Diseases 0.000 description 1
• 206010028537 myelofibrosis Diseases 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• AZBFJBJXUQUQLF-UHFFFAOYSA-N n-(1,5-dimethylpyrrolidin-3-yl)pyrrolidine-1-carboxamide Chemical compound C1N(C)C(C)CC1NC(=O)N1CCCC1 AZBFJBJXUQUQLF-UHFFFAOYSA-N 0.000 description 1
• ONDPWWDPQDCQNJ-UHFFFAOYSA-N n-(3,3-dimethyl-1,2-dihydroindol-6-yl)-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.C=1C=C2C(C)(C)CNC2=CC=1NC(=O)C1=CC=CN=C1NCC1=CC=NC=C1 ONDPWWDPQDCQNJ-UHFFFAOYSA-N 0.000 description 1
• DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
• BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
• 210000003928 nasal cavity Anatomy 0.000 description 1
• 230000002956 necrotizing effect Effects 0.000 description 1
• IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
• 229960000884 nelfinavir Drugs 0.000 description 1
• QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 201000010193 neural tube defect Diseases 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 230000003959 neuroinflammation Effects 0.000 description 1
• 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 1
• 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 1
• 208000002040 neurosyphilis Diseases 0.000 description 1
• 229960000689 nevirapine Drugs 0.000 description 1
• 201000005734 nevoid basal cell carcinoma syndrome Diseases 0.000 description 1
• 229940080607 nexavar Drugs 0.000 description 1
• 229940099637 nilandron Drugs 0.000 description 1
• ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
• 229940085033 nolvadex Drugs 0.000 description 1
• 238000013546 non-drug therapy Methods 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
• 229940127082 non-receptor tyrosine kinase inhibitor Drugs 0.000 description 1
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
• 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
• 230000000269 nucleophilic effect Effects 0.000 description 1
• 229940042404 nucleoside and nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 201000008106 ocular cancer Diseases 0.000 description 1
• 229960002450 ofatumumab Drugs 0.000 description 1
• 239000012053 oil suspension Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
• CKNAQFVBEHDJQV-UHFFFAOYSA-N oltipraz Chemical compound S1SC(=S)C(C)=C1C1=CN=CC=N1 CKNAQFVBEHDJQV-UHFFFAOYSA-N 0.000 description 1
• 229950008687 oltipraz Drugs 0.000 description 1
• 229950011093 onapristone Drugs 0.000 description 1
• 229940099216 oncaspar Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 239000000668 oral spray Substances 0.000 description 1
• 229940041678 oral spray Drugs 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 201000006958 oropharynx cancer Diseases 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• 208000002865 osteopetrosis Diseases 0.000 description 1
• 229950000193 oteracil Drugs 0.000 description 1
• 208000021284 ovarian germ cell tumor Diseases 0.000 description 1
• 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 208000005877 painful neuropathy Diseases 0.000 description 1
• AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 1
• RXBWRFDZXRAEJT-SZNOJMITSA-N palinavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)C=1N=C2C=CC=CC2=CC=1)C(C)C)[C@H](O)CN1[C@@H](C[C@@H](CC1)OCC=1C=CN=CC=1)C(=O)NC(C)(C)C)C1=CC=CC=C1 RXBWRFDZXRAEJT-SZNOJMITSA-N 0.000 description 1
• 229950006460 palinavir Drugs 0.000 description 1
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
• 208000002820 pancreatoblastoma Diseases 0.000 description 1
• 229940096763 panretin Drugs 0.000 description 1
• 208000002593 pantothenate kinase-associated neurodegeneration Diseases 0.000 description 1
• 244000045947 parasite Species 0.000 description 1
• 208000035824 paresthesia Diseases 0.000 description 1
• 230000001314 paroxysmal effect Effects 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• VMZMNAABQBOLAK-DBILLSOUSA-N pasireotide Chemical compound C([C@H]1C(=O)N2C[C@@H](C[C@H]2C(=O)N[C@H](C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](C(N[C@@H](CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)C(=O)N1)=O)CCCCN)C=1C=CC=CC=1)OC(=O)NCCN)C1=CC=CC=C1 VMZMNAABQBOLAK-DBILLSOUSA-N 0.000 description 1
• 229960005415 pasireotide Drugs 0.000 description 1
• 108700017947 pasireotide Proteins 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 229960000639 pazopanib Drugs 0.000 description 1
• 229940121655 pd-1 inhibitor Drugs 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 201000009612 pediatric lymphoma Diseases 0.000 description 1
• 229960001744 pegaspargase Drugs 0.000 description 1
• WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
• 229960005079 pemetrexed Drugs 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 208000029308 periodic paralysis Diseases 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 239000012660 pharmacological inhibitor Substances 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 229940109328 photofrin Drugs 0.000 description 1
• 235000002949 phytic acid Nutrition 0.000 description 1
• 229940068041 phytic acid Drugs 0.000 description 1
• 239000000467 phytic acid Substances 0.000 description 1
• 229950010773 pidilizumab Drugs 0.000 description 1
• 201000003113 pineoblastoma Diseases 0.000 description 1
• 210000003635 pituitary gland Anatomy 0.000 description 1
• 208000010916 pituitary tumor Diseases 0.000 description 1
• 208000010626 plasma cell neoplasm Diseases 0.000 description 1
• 229940118768 plasmodium malariae Drugs 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 108700002563 poly ICLC Proteins 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 229920002647 polyamide Polymers 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 230000003234 polygenic effect Effects 0.000 description 1
• 108010040003 polyglutamine Proteins 0.000 description 1
• 229920000155 polyglutamine Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 230000007824 polyneuropathy Effects 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 208000015768 polyposis Diseases 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 208000037955 postinfectious encephalomyelitis Diseases 0.000 description 1
• 230000001144 postural effect Effects 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• OGSBUKJUDHAQEA-WMCAAGNKSA-N pralatrexate Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CC(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OGSBUKJUDHAQEA-WMCAAGNKSA-N 0.000 description 1
• 229960004694 prednimustine Drugs 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 208000018290 primary dysautonomia Diseases 0.000 description 1
• 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
• 230000000770 proinflammatory effect Effects 0.000 description 1
• 229940087463 proleukin Drugs 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 229940048914 protamine Drugs 0.000 description 1
• 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
• 229940063222 provera Drugs 0.000 description 1
• 208000001381 pseudotumor cerebri Diseases 0.000 description 1
• 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
• IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
• 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 238000000163 radioactive labelling Methods 0.000 description 1
• 229940099538 rapamune Drugs 0.000 description 1
• 108700042226 ras Genes Proteins 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 208000020615 rectal carcinoma Diseases 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 230000003252 repetitive effect Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 230000004044 response Effects 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 229940120975 revlimid Drugs 0.000 description 1
• OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 229940046939 rickettsia prowazekii Drugs 0.000 description 1
• 229940075118 rickettsia rickettsii Drugs 0.000 description 1
• 229960000311 ritonavir Drugs 0.000 description 1
• NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
• 229960003522 roquinimex Drugs 0.000 description 1
• HHJUWIANJFBDHT-ZVTSDNJWSA-N rsa8ko39wh Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 HHJUWIANJFBDHT-ZVTSDNJWSA-N 0.000 description 1
• ZCBUQCWBWNUWSU-SFHVURJKSA-N ruboxistaurin Chemical compound O=C1NC(=O)C2=C1C(C1=CC=CC=C11)=CN1CCO[C@H](CN(C)C)CCN1C3=CC=CC=C3C2=C1 ZCBUQCWBWNUWSU-SFHVURJKSA-N 0.000 description 1
• 229950000261 ruboxistaurin Drugs 0.000 description 1
• INBJJAFXHQQSRW-STOWLHSFSA-N rucaparib camsylate Chemical compound CC1(C)[C@@H]2CC[C@@]1(CS(O)(=O)=O)C(=O)C2.CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23 INBJJAFXHQQSRW-STOWLHSFSA-N 0.000 description 1
• 239000004248 saffron Substances 0.000 description 1
• 235000013974 saffron Nutrition 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 201000003804 salivary gland carcinoma Diseases 0.000 description 1
• 229960001852 saquinavir Drugs 0.000 description 1
• QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 108010038379 sargramostim Proteins 0.000 description 1
• 229960002530 sargramostim Drugs 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 201000004409 schistosomiasis Diseases 0.000 description 1
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
• 229950000055 seliciclib Drugs 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 208000005893 serous cystadenoma Diseases 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 201000008261 skin carcinoma Diseases 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 208000019116 sleep disease Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• JJICLMJFIKGAAU-UHFFFAOYSA-M sodium;2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)purin-6-olate Chemical compound [Na+].NC1=NC([O-])=C2N=CN(COC(CO)CO)C2=N1 JJICLMJFIKGAAU-UHFFFAOYSA-M 0.000 description 1
• RMLUKZWYIKEASN-UHFFFAOYSA-M sodium;2-amino-9-(2-hydroxyethoxymethyl)purin-6-olate Chemical compound [Na+].O=C1[N-]C(N)=NC2=C1N=CN2COCCO RMLUKZWYIKEASN-UHFFFAOYSA-M 0.000 description 1
• MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 229940055944 soliris Drugs 0.000 description 1
• 229940034810 soltamox Drugs 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 235000010356 sorbitol Nutrition 0.000 description 1
• 229950007213 spartalizumab Drugs 0.000 description 1
• 208000018198 spasticity Diseases 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 208000037959 spinal tumor Diseases 0.000 description 1
• 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 description 1
• 201000004284 spotted fever Diseases 0.000 description 1
• 208000017572 squamous cell neoplasm Diseases 0.000 description 1
• 208000037969 squamous neck cancer Diseases 0.000 description 1
• 229960001203 stavudine Drugs 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 1
• 208000034223 susceptibility to 2 systemic lupus erythematosus Diseases 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 208000002025 tabes dorsalis Diseases 0.000 description 1
• ZMELOYOKMZBMRB-DLBZAZTESA-N talmapimod Chemical compound C([C@@H](C)N(C[C@@H]1C)C(=O)C=2C(=CC=3N(C)C=C(C=3C=2)C(=O)C(=O)N(C)C)Cl)N1CC1=CC=C(F)C=C1 ZMELOYOKMZBMRB-DLBZAZTESA-N 0.000 description 1
• 229940120982 tarceva Drugs 0.000 description 1
• RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• 229960001674 tegafur Drugs 0.000 description 1
• WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
• 229960002935 telaprevir Drugs 0.000 description 1
• 108010017101 telaprevir Proteins 0.000 description 1
• 201000004415 tendinitis Diseases 0.000 description 1
• 229960004556 tenofovir Drugs 0.000 description 1
• VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
• BEUUJDAEPJZWHM-COROXYKFSA-N tert-butyl n-[(2s,3s,5r)-3-hydroxy-6-[[(2s)-1-(2-methoxyethylamino)-3-methyl-1-oxobutan-2-yl]amino]-6-oxo-1-phenyl-5-[(2,3,4-trimethoxyphenyl)methyl]hexan-2-yl]carbamate Chemical compound C([C@@H]([C@@H](O)C[C@H](C(=O)N[C@H](C(=O)NCCOC)C(C)C)CC=1C(=C(OC)C(OC)=CC=1)OC)NC(=O)OC(C)(C)C)C1=CC=CC=C1 BEUUJDAEPJZWHM-COROXYKFSA-N 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 201000006361 tethered spinal cord syndrome Diseases 0.000 description 1
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
• BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
• 229960003433 thalidomide Drugs 0.000 description 1
• 229940034915 thalomid Drugs 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 206010048627 thoracic outlet syndrome Diseases 0.000 description 1
• 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• 229960000838 tipranavir Drugs 0.000 description 1
• SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
• 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
• 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 1
• 210000002105 tongue Anatomy 0.000 description 1
• 201000006134 tongue cancer Diseases 0.000 description 1
• 208000025358 tongue carcinoma Diseases 0.000 description 1
• 229940035307 toposar Drugs 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 229940100411 torisel Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 201000010875 transient cerebral ischemia Diseases 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 229910052723 transition metal Inorganic materials 0.000 description 1
• 150000003624 transition metals Chemical class 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 208000009174 transverse myelitis Diseases 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 230000009529 traumatic brain injury Effects 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 229950007217 tremelimumab Drugs 0.000 description 1
• 150000004654 triazenes Chemical class 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
• 206010044652 trigeminal neuralgia Diseases 0.000 description 1
• 229940071559 trioxin Drugs 0.000 description 1
• 229960004824 triptorelin Drugs 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 208000009999 tuberous sclerosis Diseases 0.000 description 1
• 208000032471 type 1 spinal muscular atrophy Diseases 0.000 description 1
• 208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
• 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 201000009825 uterine corpus cancer Diseases 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• XGOYIMQSIKSOBS-UHFFFAOYSA-N vadimezan Chemical compound C1=CC=C2C(=O)C3=CC=C(C)C(C)=C3OC2=C1CC(O)=O XGOYIMQSIKSOBS-UHFFFAOYSA-N 0.000 description 1
• 229950008737 vadimezan Drugs 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 229960000653 valrubicin Drugs 0.000 description 1
• 229940054937 valstar Drugs 0.000 description 1
• LLDWLPRYLVPDTG-UHFFFAOYSA-N vatalanib succinate Chemical compound OC(=O)CCC(O)=O.C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 LLDWLPRYLVPDTG-UHFFFAOYSA-N 0.000 description 1
• 235000019871 vegetable fat Nutrition 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 229940099039 velcade Drugs 0.000 description 1
• JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 1
• 210000001048 venom Anatomy 0.000 description 1
• 239000002435 venom Substances 0.000 description 1
• 231100000611 venom Toxicity 0.000 description 1
• 238000012795 verification Methods 0.000 description 1
• 229960003895 verteporfin Drugs 0.000 description 1
• 229940061389 viadur Drugs 0.000 description 1
• 229940065658 vidaza Drugs 0.000 description 1
• AQTQHPDCURKLKT-PNYVAJAMSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 1
• NMDYYWFGPIMTKO-KLCPSUAYSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-KLCPSUAYSA-N 0.000 description 1
• GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 230000009278 visceral effect Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 229940061392 visudyne Drugs 0.000 description 1
• 208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
• 229960000237 vorinostat Drugs 0.000 description 1
• 229960001771 vorozole Drugs 0.000 description 1
• XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
• 229940069559 votrient Drugs 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 235000021119 whey protein Nutrition 0.000 description 1
• NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 1
• 229960000523 zalcitabine Drugs 0.000 description 1
• 229960002555 zidovudine Drugs 0.000 description 1
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1
• 239000011787 zinc oxide Substances 0.000 description 1
• 235000014692 zinc oxide Nutrition 0.000 description 1
• 229940033942 zoladex Drugs 0.000 description 1
• 229940061261 zolinza Drugs 0.000 description 1